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Preface
This book Pain Management has 7 chapters, from more than 15 authors from different count‐
ris (Korea, Poland, Saudi Arabia, Taiwan, Turkey and USA) of the world and one editor,
Professor Milica Prostran. Professor Prostran, MD, PhD is a pharmacologist as well as a clin‐
ical pharmacologist with subspeciality in clinical pharmacology - pharmacotherapy. This
was due to her experience with publishing in respected international journals: she published
over 180 in extenso papers in peer review international journals indexed in CC/SCI, and over
50 chapters in various books, Professor Prostran has compiled a collection of manuscripts
(see List of her selected references at the end of this text).
Topics covered in Pain Management vary among Acute pain management in the emergency de‐
partment, The quality of prehospital care give to children with traumatic injuries, Managing pain
with laser acupuncture, Pain management of Herpes Zoster, Pain management in knee osteoarthritis,
Application of radiofrequency in pain management to Epiduroscopy (Epidural endoscopy).
The most common complaint in the Emergency Department is pain. According to authors of
this chapter (Samcam and Papa), "objectively assessing and documenting a patient’s pain is
the key to determining treatment. The approach to a patient with acute pain requires an ex‐
perienced clinician who is awere of the pharmacology of analgesics and anesthetics, contra‐
indications, precautions, side effects, administration methods and monitoring
requirements."
Rutkowska et al. concluded among other things that "The management of the child with an
injury in the Lodzkie region (in Poland) is unsatisfactory. Despite the training of physicians,
nureses and paramedics in the management of paediatric injuries, the lack of analgesic pro‐
vision is still encountered in almost half of patients, irregularities in transport immobilisa‐
tion - in about 10% of the patients and irregularities in wound management and IV access
provision - in isolated cases. In 1/4 of the cases, gaps in medical records were also noted."
Wu et al. presented a paper dealing with laser acupuncture, introduced clinically for the
first time in the 1970s. They stated that "Laser acupuncture relieves pain through both anti-
inflammatory and analgesic effects. No adverse effects or complications resulting from laser
acupuncture were reported in the litarature. In the hands of an experienced physician, laser
acupuncture can be a useful and safe method for pain management."
Jung and Park in their review focused on the treatment options available for management of
patients with acute HZ (Herpes Zoster) and PHN (Post-Herpetic Neuralgia), while Anwer
and Alghadir, stated that "Management of knee OA ofter requires a combination of pharma‐
cologic and nonpharmacologic treatment approaches."
Deniz et al. stated "…the use of continuous and pulsed radiofrequency with a minimal inva‐
sive procedure for patients with chronic pain as an alternative to surgical treatment and it
might be an additional option among nonsurgical treatment methods."
And, the last chapter deals with epidural endoscopy in detail. Sayhan and Beyaz concluded
that "Incidence of complications is inversely proportional to professional skills of practition‐
er and the number of years of experience. It should be borne in mind, there are risk associat‐
ed with medical procedures in the spinal region, even when it is performed properly and
conscientiously."
The potential reader is shown the modern approach to pain management because the chap‐
ters deal at length and clearly with the topics.
I believe that this book Pain Management I edited with great pleasure and dedication will
capture the attention of many readers, from medical students, practicing medical doctors as
well as biomedical researchers. All of them need to deal with this extremely important field
of treating pain. Additionally, I do believe that the answers they may find in Pain Manage‐
ment will make their practice easier. Also, the life of their patients will be considerably more
pleasant, or at least more bearable.
Last but not least, I want to express my gratitude to Ms. Ana Simčić, publishing process
manager from InTech for her constant help in editing this book.
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Abstract
The most common presenting complaint to the emergency department (emergency room)
is pain. Unfortunately, pain is still undertreated in this setting. Literature has shown that
treatment of pain not only improves patient satisfaction but also improves mood, decreases
length of hospital stay, and decreases mortality. Various pharmacological options are
available for treating acute pain, ranging from oral, intravenous, and intramuscular
medications; topical agents; and peripheral nerve blocks. Objectively assessing and
documenting a patient’s pain is the key to determining treatment. The approach to a
patient with acute pain requires an experienced clinician who is aware of the pharma‐
cology  of  analgesics  and  anesthetics,  contraindications,  precautions,  side  effects,
administration methods, and monitoring requirements.
This chapter briefly covers the pathophysiology of acute pain and the different treat‐
ment modalities available to the emergency physician.
Keywords: pain, acute, emergency, treatment, management
1. Introduction
1.1. Epidemiology
The most common presenting complaint to the emergency department (ED) room is pain. From
1996 to 2015, ED visits have risen over 46%, from 90.3 million to [1] 136 million [1, 2]. As
emergency room visits continue to grow every year, so does the need to treat patients in pain.
Roughly, 45% of ED visits involves either moderate or severe pain [3]. The most common pain-
related chief complaints in descending order are chest pain, back pain, and headache. Fur‐
thermore, the most frequently ordered analgesics, both in the ED and at discharge, are
acetaminophen (alone or in combination with hydrocodone), ketorolac, and ibuprofen [3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1.2. Oligoanalgesia
Despite the trend in increasing ED visits of which the majority involves pain, pain is still
undertreated in the ED. Oligoanalgesia is a term used to describe the inadequate treatment of
pain and was first studied in a retrospective chart analysis in 1989 by Wilson and Pendleton
[4]. In this study, a total of 198 patients were evaluated, and of those who received analgesics,
32% received less than optimal doses [5]. An additional retrospective study, done a few years
later, revealed that only 30% of 401 patients treated for bone fractures received analgesics [6].
In a separate study, patients were surveyed after treatment in a fast-track area of the emergency
room, and 60% of patients went home with more pain than they were willing to accept [7].
More recently, a prospective, multicenter study enrolled 842 patients (aged 8 years and older)
across 20 US and Canadian EDs with presenting pain intensity scores of 4 or greater on an 11-
point numerical rating scale and found that only 60% of patients received analgesics, and 74%
of patients were discharged in moderate to severe pain. Furthermore, reassessments were
uncommon, and analgesics were administered after lengthy delays (median, 90 minutes;
range, 0–962 minutes) [8].
1.3. Why is treating pain important?
The Joint Commission on Accreditation of Hospitals Organization (JCAHO) has recommended
that assessment and treatment of pain be improved. Moreover, patients expect to have their
pain treated fairly quickly and to have it significantly reduced. Studies have shown that
patients want their pain treated in less than half an hour, yet the mean time of treatment is at
least 78 minutes [9]. Acknowledging and treating pain in the ED improves the rapport between
physician and patient. Patients are more likely to characterize physicians who treat their pain
as warm and friendly and inspire more confidence to discuss their private health concerns [10].
Inadequately treating pain can contribute to the development of comorbidities such as
depression, hypertension, and immune system dysfunction [10].
There are numerous potential reasons for which pain is inadequately treated in the ED, such
as concern of masking symptoms, poor communication between clinician and patient (lan‐
guage, cultural), lack of documentation and reassessment of pain, and fear of contributing to
and causing addiction. One of the most cited reasons is the concern that analgesics, particularly
opioids, may mask symptoms of a surgical abdomen. This concern has been refuted by a
number of studies. A randomized double-controlled trial conducted in 2002 evaluated pain
control in the diagnosis of appendicitis. Pain was adequately treated, and patients continued
to have pain upon palpation on physical examination [11]. An additional study studied the
surgeon’s confidence in physical signs after administration of morphine to patients with
appendicitis. Despite the morphine, these surgeons continued to illicit examination signs such
as the obturator sign, Rovsing, and pain upon jumping [12]. Other physicians may argue that
opioids may mask the intensity of pain allowing for the progression of the illness to compli‐
cations such as perforation and formation of an intra-abdominal abscess. A systematic review
of six randomized controlled trials evaluating the safety of opioid administration to children
with acute abdominal pain showed no significant difference in the rate of perforation or abscess
formation [13]
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The concern over causing addiction plays an important role in oligoanalgesia in the ED. In
2012, health care providers wrote 259 million prescriptions for painkillers. This is equivalent
to every American adult having a bottle of pills. Furthermore, each day, 46 people die from an
overdose of prescription painkillers in the United States [14].
In 2007 the cost of prescription opioid abuse was estimate to be $56 billion dollars [15]. Those
with a prior history of depression, anxiety, and substance use were most likely to have a
propensity for prescription opioid abuse [16]. An additional study confirmed mental disease
as risk factor for opioid abuse, as well as males, younger adults, and individuals with greater
days of supply of prescription opioid abuse. Thus, the emergency physician must do a full
history, including a psychiatric history, prior to considering opioids.
Screening programs not only elucidate a patient’s past-filled prescriptions but can also give
the physician an idea of the different pharmacies and health clinics the patient has gone to.
This information gives the prescriber insight into any drug-seeking behavior and may change
their propensity into prescribing a certain analgesic [17].
1.4. Documentation of pain
The effective management of acute pain in the ED requires appropriate assessment of the pain
based on the patient’s perception of pain using a validated pain scale. Additionally, reassess‐
ment of pain is essential to determine the effect of treatment. Pain has been described as a vital
sign, and as such it should be documented in the initial assessment of a patient. Verbal pain
scores (VPSs) may reveal those who are truly in pain but who may not voice their discomfort,
as well as influence the physician to inquire about the patient’s pain. One study revealed, that
in patients who did not receive analgesics, 42% desired them, but only 31% voiced their concern
[8]. A prospective study introducing VPSs in an ED revealed that of those trauma patients who
had VPS scores documented, 60% received analgesics versus 33% in those who did not have
a VPS score documented. Furthermore, those with higher VPS scores were more likely to
receive analgesics [18]. ED crowding has been shown to increase time to analgesic adminis‐
tration and mortality [19]. The use of VPS in this setting may identify those individuals in need
of quicker treatment.
2. Pathophysiology
Pain can be divided into acute and chronic, with acute pain being incited by a traumatic injury
or pathologic condition. As the causative issue is addressed, acute pain is usually resolved.
Acute pain is mediated through nociceptors, of which there are various types ranging from
mechanical to thermoreceptors. These receptors are stimulated by chemical, thermal, or
mechanical stimuli [20]. As these receptors are stimulated, sensory neurons transmit the
stimulus through neuronal pathways made up of various peripheral nerve fibers. “First Pain,”
which is well localized and sharp, is modulated by Aδ-fibers. The second component of pain,
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or the slow phase, is conducted by C fibers and is characterized by dull and poorly localized
pain [21].
All pain starts as acute pain; however, not all pain progresses to chronic pain. Acute pain
becomes chronic when pain persists despite the resolution of the inciting event. There may be
many causative factors that account for prolonged pain. Apart from the psychosocial influen‐
ces on chronic pain development, physiologic factors that contribute to chronic pain include
alterations in the spinal cord that occur when acute pain is inadequately treated. These changes
lead to increased excitability, decreased inhibition, and reorganization of certain spinal tracts
[22]. The time frame for defining chronic pain varies from 3 to 6 months of ongoing pain.
However, some would argue that chronic pain is any pain that persists longer than the
reasonably expected healing time for the involved tissues. It is also important to understand
that an individual’s perception of pain may be influenced by culture, previous painful
experiences, beliefs, mood, and ability to cope.
2.1. Somatic and visceral pain
Somatic pain is made up of mostly A-fibers and is located in cutaneous tissues as well as deep
tissues such as fascia, tendons, or bone. This pain is described as initially sharp and then as
burning or throbbing. On the contrary, visceral pain is primarily composed of C f-fibers, and
its primary afferent neuron endings are usually found in internal organs such as intestines,
gonads, or heart [21]. For example, at presentation, pain from appendicitis may initially be
poorly localized around the periumbilical site and characterized as dull, indicating primarily
a visceral pain. However, as inflammation continues, the above fascia tissues become inflamed.
At this point, pain is now located at the right lower quadrant and may be sharp. This later
presentation of appendicitis is now primarily involving the somatic cutaneous nerves in the
corresponding dermatome. Asking the patient to initially describe the pain may hint toward
the initial causative pathologic condition. For instance, in a patient with sharp and clearly
localized back pain, the causative agent may be musculoskeletal in nature. However, those
with dull, achy, and poorly localized pain, back pain radiating to the groin may be due to an
internal cause such as pyelonephritis or nephrolithiasis.
2.2. Neuronal pathway
The initiating stimulus of pain is conducted through these peripheral nerve fibers. There are
a number of neuronal pathways through neuronal pathways, but the spinothalamic tract is
the main pathway. These pathways converge into primary afferent neurons found in the dorsal
root ganglion. Afferent neurons have two endings: one signaling the peripheral system and
the second signaling second-order neurons in the dorsal horn. The second-order neurons’
axons cross the midline of the spinal cord into the contralateral spinothalamic tract, where they
ascend into the thalamus. Third-order neurons in the thalamus synapse with the second-order
neurons and send signals to the post-central gyrus of the cerebral cortex [21]. As the nerve
fibers ascend in the spinal cord, they organize into dorsolateral columns and anteromedial
segments [20].
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The dorsal columns and anterior medial segment are divided into different segments called
laminae. This is done to organize the type of sensory information sent into each section [23].
Laminae 1 through 6 are located in the dorsal horn, 7 through 10 in the intermediate zone, and
8 though 9 in the anterior/ventral horn. The gray matter surrounding the central cord composes
lamina 10. All afferent nerve activity is received in the dorsal horn. Specifically, lamina 1
receives mostly noxious stimuli from cutaneous tissues and deep somatic tissues. Visceral
afferent fibers are transmitted to laminas 5 and 1. However, lamina 5 also receives somatic
afferent fibers, and it is this convergence that leads to referred pain [21]. Lamina 2, or the
substantia gelatinosa of Rolando, mediates the activity of pain and temperature afferent fibers.
Next, lamina 3 and 4, known as the nucleus proprius, receive input from lamina 2 and also
help regulate pain, temperature, as well as crude touch. Lamina 7 receives afferent input from
muscle fibers and joints [24].
Furthermore, the spinothalamic tract is subdivided into a lateral and a medial tract. The lateral
tract projects to the ventral posterolateral nucleus of the thalamus and carries fibers sensory
input that transmits location, intensity, and duration of pain. The medial tract projects to the
medial nucleus of the thalamus and mediates the emotional and autonomic aspects of pain.
Collateral fibers from the spinothalamic tract are also projected to the RAS, or reticular
activating system, as well as the hypothalamus [21]. These collateral fibers may be responsible
for the arousal aspect of pain.
2.3. Modulation of pain
Descending tracts originating from the midbrain and medulla feed into the spinal cord through
the dorsolateral funiculus, modulating pain [20]. For example, stimulation of the periaque‐
ductal gray, through projections from the spinothalamic tract, provides widespread analgesia
in humans [25, 26]. One investigator noted that stimulation of the periaqueductal gray leads
to analgesia with such significance that one could perform an exploratory laparotomy without
any chemical anesthesia [26, 27]. Furthermore, these tracts involve transmitters such as
norepinephrine, serotonin, and opiates [20]. TCAs and SSRIs through these neurotransmitters
have been shown in various studies to significantly reduce chronic pain, regardless of the
patient’s psychosocial status. A meta-analysis found there is no difference in pain relief from
the use of these medications in the absence or presence of depression, and the size of analgesia
is not significantly different in the presence or absence of anti-depressant effect [28].
Additional modulation of pain can be seen through the endorphin system. This system consists
of neurons that secrete three types of opioids beta-endorphin, net- and leu-enkaphalins, and
dynorphins. These chemicals act on the mu, delta, and kappa receptors modulating pain relief
[20].
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3. Common analgesic agents used in the emergency department
3.1. Opioids
Opioid prescriptions for the management of non-cancer pain have increased over the last 10–
20 years. Concerns of opioid dependence and toxicity, such as respiratory depression, have
led to the under-dosing of these agents in the ED and the use of other less effective analgesic
agents.
3.1.1. Mechanism
The term opioid refers to natural and synthetic substances that act at one of the three main
opioid receptor systems (mu, kappa, delta). They can have analgesic and central nervous
system (CNS) depressant effects as well as the potential to cause euphoria. The majority of
opioids used clinically target μ-opioid (mu) receptors. These receptors mediate analgesia as
well as common side effects such as euphoria, constipation, and respiratory depression [29].
One exception is the combination of agonist–antagonist agents such as buprenorphine.
Another less commonly targeted receptor is the κ-opioid (kappa) receptor, which is important
in regulating GI motility and dysphoria. The other endorphin receptors may regulate neuro‐
pathic pain, as we all as spinal anesthesia.
3.1.2. Morphine
One of the most commonly used opioids in the ED is morphine. It is considered safe and
effective in the monitored setting in the ED [29].
Side effects can range from hypotension, pruritus, nausea, vomiting, and respiratory depres‐
sion. It is believed that some of these side effects may be due to the destabilization of mast cells
that lead to the release of histamine. Respiratory depression is caused by desensitization of the
medulla to carbon dioxide, through opioids binding to the mu receptor. The cardiovascular
effects of opioids are mediated centrally at the central vagal nucleus and, in the case of
morphine, directly into the sinoatrial node. Within the gastrointestinal system, opioids delay
gastric emptying and cause constipation [29]. There appears to be no significant differences in
side effects between dosages of 0.1 mg/kg and 0.15 mg/kg.
Weight-based dosing for morphine is not necessary in obese patients. A prospective observa‐
tional study in the ED revealed that patient’s weight was not predictive of pain reduction [30].
Thus one should start with the recommended dose of 0.1 mg/kg if side effects are of concern;
however, one should be ready to rebolus in 5–15 minutes as studies have revealed this initial
dosing is inadequate. A prospective cohort study of 119 patients revealed that 67% of patients
who received 0.1 mg/kg of morphine stated less than 50% reduction of pain 30 minutes later
[31]. A later study evaluating trauma patients revealed that a dose of 0.15 mg/kg when
compared to 0.1 mg/kg significantly reduces pain without any significant difference in adverse
events [32].
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In the setting of trauma, hypotension may reduce tissue perfusion in patients with significant
blood loss. However, in a randomized controlled study in acute trauma patients, hypotension
only occurred in 10% of patients who received morphine [32]. A study investigating the use
of morphine in the pre-hospital setting in ST segment elevation myocardial infarction patients
found no worsening of in-hospital complications or 1-year mortality [33]. The cancer literature
has also shown the value and safety of morphine infusions for pain control [34].
3.1.3. Hydromorphone
Hydromorphone is a semisynthetic derivative of morphine that is seven times more potent
than morphine. Despite the increased potency, studies have shown that nurses who are
concerned about side effects may give a lower dose of morphine versus hydromorphone since
the “total milligrams” given in hydromorphone is less when compared to an equal analgesic
dose of morphine [35]. Despite the dosing difference, hydromorphone appears to offer better
pain control. In a retrospective study involving the use of patient-controlled analgesia (PCA)
with either morphine or hydromorphone, more patients receiving morphine required rescue
analgesia due to initial inadequate pain control [36].
Pruritus occurs less frequently with hydromorphone. Hydromorphone is conjugated by the
liver to hydromorphone-3-glucoronide, an inactive metabolite. However, morphine’s metab‐
olite is active, and as a result, hydromorphone is better tolerated [20]. With regard to adverse
effects, hydromorphone has not been shown to have an increased risk, and its use does not
necessitate increased naloxone administration [37].
3.1.4. Fentanyl
When pain relief is needed quickly for acute severe pain, such as in trauma, fentanyl may be
of use. Its time of onset is 1–2 minutes and lasts typically about 30 minutes [20]. The initial IV
dose is 1.5 μg/kg, and it has the advantage of a short half-life. This is particularly useful if serial
examinations are needed. Fentanyl causes minimal histamine release, making it ideal in
patients in whom blood pressure must be maintained. For example, in severe traumatic brain
injury patients, in whom MAP must be kept above 80 to maintain cerebral perfusion pressure,
and must be examined serially, fentanyl may be a useful analgesic. The safety profile is
favorable, particularly in the pre-hospital setting. A retrospective chart review of 2,129 patients
transported by Emergency Medical Services revealed that fentanyl affected vital signs in less
than 1% of patients [38]. Despite its favorable hemodynamic profile, fentanyl may cause chest
wall rigidity when given in doses above 15 μg/ kg leading to inadequate ventilation. This is a
rare complication and can be remedied through neuromuscular blockade or naloxone [39, 40].
3.2. Non-opioid medications
Non-opioid analgesics include acetaminophen, non-selective nonsteroidal anti-inflammatory
drugs (NSAIDs), and cyclooxygenase 2 (COX-2) inhibitors. NSAIDs and COX 2 inhibitors have
anti-inflammatory properties.




A common over-the-counter analgesic for mild to moderate pain is acetaminophen (para-
acetylaminophenol) or paracetamol (in Europe). Its mechanism of action is through the
inhibition of prostaglandin endoperoxide H2 synthase and cyclooxygenase activity [20, 41]. Its
central anti-pyretic effect is of great use when fever needs to be reduced. It has been shown to
have good analgesic effects; however, acetaminophen is not anti-inflammatory. Systematic
reviews have shown that acetaminophen can significantly reduce pain; however, it may be
less effective than NSAIDs in conditions such as back pain and osteoarthritis [42–44]. Acet‐
aminophen can also be combined with opioid medications to reduce the amount of opioid
needed. However, concerns about unintentional acetaminophen overdose have led to combi‐
nation drug products with more than 325 mg acetaminophen per tablet to be withdrawn from
the market. Acetaminophen overdose can lead to severe hepatotoxicity and should be used
cautiously in patients with chronic alcohol use or liver disease.
Intravenous acetaminophen is being studied for acute pain such as in acute traumatic limb
injuries [45] or rib fractures [46] or in postoperative patients [47, 48]. It has also been shown to
reduce the need for rescue pain medications such as opioids [49, 50].
3.2.2. Nonsteroidal anti-inflammatory drugs
NSAIDs provide analgesia for mild to moderate pain and also work synergistically when
paired with opioids. They work through the inhibition of cyclooxygenase by decreasing the
production of prostaglandins and prostacyclins, primarily cyclooxygenase 1 (COX-1) and
COX-2. COX-1 mediates platelet aggregation and maintenance of gastrointestinal mucosal
integrity. By contrast, COX-2 generates prostaglandins that mediate pain and inflammation
[29]. The different NSAIDs can be either selective COX-2 inhibitors or non-selective, thus
differing in their side-effect profile. There are many NSAIDs to choose from, but there is little
literature showing improved efficacy of one NSAID over another.
Main adverse side effects of NSAIDs include gastrointestinal insult, renal insult, inhibition of
platelets, cardiovascular effects, and anaphylaxis. Renal failure is caused by the decreased
production of prostaglandins, which aid in afferent glomerular arteriole vasodilation. NSAIDs
contribute to arteriolar vasoconstriction, leading to decreased renal perfusion pressure and
decreased glomerular filtration rates [51]. This is worsened by dehydration. As selectivity of
COX inhibition increases, the renal effects decrease. NSAIDs such as ketorolac and diclofenac
have fewer effects on the kidney than naproxen or ibuprofen [51, 52].
The most common side effect of NSAIDs is gastrointestinal injury, such as bleeding or
dyspepsia and gastric ulceration. Patients who are at high risk for peptic ulcer disease or its
complications, such as the elderly, those with bleeding diathesis, or patients on glucocorti‐
coids, have a relative contraindication to the use of an NSAID. Each NSAID has variability in
the risk of gastrointestinal injury it poses. This is due to the selectivity of COX-1 inhibition, so
that the relative risk of for ibuprofen is 2.6, while the relative risk for ketorolac is 14.5 [51, 53].
Various studies have shown that COX-2 inhibition is related to increased cardiovascular risk.
This is believed to be the result of decreased prostacyclin (prostaglandin I2) and increased
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thromboxane A2. The effects lead to hypertension, accelerated atherogenesis, and increased
thrombotic response to plaque rupture [54]. Myocardial infarction was found to be increased
in this class of NSAIDs, resulting in the discontinuation of rofecoxib [55, 56]. Furthermore, it
has been shown that specific COX-2 inhibitors may also further inhibit renal perfusion and
lead to decreased sodium excretion, which may further worsen congestive heart failure and
renal function [57, 58]. Due to COX-2 specific inhibitor side-effect profile and no proven
increased efficacy over non-selective NSAIDs, there is minimal to no advantage in using this
class in the ED.
There has been no proven efficacy over one type of NSAID, including the route of adminis‐
tration such as intra-muscular versus oral [29, 59, 60]. One should select a particular NSAID
based on its side-effect profile and the route of administration that is the most feasible for the
patient. Furthermore, prior to using NSAIDs, one must also take into consideration that this
class of pharmaceuticals is most useful when used in pain mediated by prostaglandins or
inflammation, not in other situations such as neuropathic pain. For instance, NSAID, partic‐
ularly ketorolac, has been shown to significantly reduce pain in renal colic, and has similar
efficacy in pain reduction as morphine [61]. When used in combination, opiates and NSAIDs
may reduce the need of additional doses of analgesic rescue therapy in renal colic and have
greater pain efficacy than either drug used alone [62]. In acute lower back pain, NSAIDs have
been shown to significantly reduce pain and improve daily function [63]. The addition of
opioids in this setting of pain was not proven to be more effective than NSAIDs alone [64].
3.2.3. Antispasmotics (muscle relaxants)
Muscle relaxants have been used by the physicians with the intention of alleviating muscu‐
loskeletal pain. However, data on this class of medications have produced mixed results since
their action may be more the result of sedation rather than muscle relaxation. A systematic
review, evaluating the effectiveness of cyclobenzaprine in lower back pain, revealed short-
term improvement of pain at 7 days. However, there was no improvement of pain at 14 days,
and there was no statistical difference when compared to diazepam [65]. Furthermore, in a
second review evaluating the effectiveness of muscle relaxants in neck pain, there was no
difference when compared to placebo at 2 weeks [66].
When compared to NSAIDs, muscle relaxants have been shown to have no significant
difference in pain relief or improvement in daily function. Moreover, there is little to no added
benefit when using muscle relaxants together with NSAIDs [64, 67]. Given the limited data on
muscle relaxants, one should consider the side effects. Major side effects range from
drowsiness, dizziness, dry mouth as well as other anticholinergic effects. These medications
should only be prescribed for short-term use, given the limited data regarding efficacy past 1
week. In addition, one should refrain from prescribing these medications in the elderly, as they
are at higher risk of falls and delirium.




There are various topical agents ranging from patches, gel, sprays to creams, which may aid
in relieving pain. They appear to have several potential advantages over systemic drugs such
as delivery at the site of injury, lower levels of systemic absorption, and fewer systemic effects.
Although systemic side effects are not as frequent as oral formulations, significant systemic
concentration can be achieved by topical application.
Often, these agents have similar efficacy to their oral preparations. For example, a randomized
controlled trial comparing a gel preparation of ibuprofen versus oral tablets revealed compa‐
rable improvement in patient’s pain and functional status at 2 weeks [68]. Topical agents often
have fewer side effects than their oral counterparts, and most adverse events are primarily
cutaneous in nature such as rashes or pruritus. Decreased adverse events may be due to lower
bioavailability in the plasma [69, 70]. Many factors may influence the penetration of the topical
agent into the local site. Variability in an individual’s skin properties such as the thickness of
stratum corneum may be a limiting factor. Furthermore, the agent must be lipophilic and
water-soluble [71]. Local site pH, such as acidity in a local cellulitis, may also limit penetration
of the agent.
Topical NSAIDs have been shown to have rare incidences of gastrointestinal adverse events
such as ulcer formation, as opposed to oral formulations [69]. Topical diclofenac and ibuprofen
have been shown to be effective in acute soft tissue injuries, such as ankle sprains as well as
arthritic knee pain [68, 72, 73]. Furthermore, topical diclofenac has been shown to be effective
in reducing myofascial pain, however, with no effect on the myofascial trigger point pain
threshold [74]. Topical NSAIDs have been shown to have equal efficacy as oral NSAIDs, yet
various studies have shown topical diclofenac to reduce pain within 2–3 days of treatment [72,
75–77].
Neuropathic pain has been shown to respond to topical agents. For example, topical lidocaine,
when used in post-herpetic neuralgia (PHN), has been associated with improved quality of
life, improvement of pain and allodynia [78]. Moreover, when compared with oral pregabalin,
response rates were higher in patients with either PHN or diabetic neuropathy. The same
studies also showed a lower rate of adverse events and improved quality of life [77, 79, 80].
Topical capsaicin cream has also been studied to reduce neuropathic pain; nonetheless,
application of this cream has been associated with a burning sensation in up to 81% of patients
[81]. Randomized controlled studies of high concentration topical capsaicin revealed signifi‐
cant pain relief in patients with PHN with relief lasting up to 12 weeks [77, 82, 83].
Topical opioids have not been shown to significantly reduce pain. For example, a randomized
controlled trial comparing the use of topical morphine sulfate versus traditional Jelonet
dressings in burn patients revealed increased need of rescue analgesia and higher pain scores
in the topical morphine group [84]. Another study revealed no significant reduction in pain
with patients with skin ulcers when topical morphine was compared to placebo [85]. However,
in patients with mucositis undergoing chemoradiotherapy for head and neck cancer, oral
morphine mouthwash has been shown to significantly reduce pain and reduce length of
functional impairment [86]
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In summary, topical analgesics may provide additional analgesia in patients who may not be
able to tolerate the adverse effects of systemic analgesics. Those with PHN may benefit from
topical lidocaine when amitriptyline fails to provide relief. Those with peptic ulcer disease
may benefit from topical NSAIDs to treat arthritis, as oral NSAIDs may worsen their condition.
By contrast, topical opioids have not been shown to provide significant relief in burns or skin
conditions, limiting their role in the ED.
3.3. Peripheral nerve blocks
There are two types of nerve blocks: single injection and continuous nerve blocks.
Single-injection nerve blocks are one-time injections of local anesthetic adjacent to the nerve
or plexus for anesthesia and/or analgesia and are most commonly used in the ED. Continuous
infusion nerve blocks involve the placement of catheter adjacent to the peripheral nerve or
plexus. These are useful in patients who are expected to have prolonged need for analgesia.
The effectiveness and duration of the block depend upon the pharmacology of the analgesic/
anesthetic agent used, the dose, and the concentration.
Peripheral nerve blocks are important tools for pain management in the ED and have been
shown to significantly reduce pain. Analgesia from peripheral nerve blocks can be reached
more quickly than intravenous narcotics and often with more efficacy and less rescue analge‐
sics. A randomized controlled trial compared the use of femoral nerve blocks versus intrave‐
nous narcotics in femoral fractures and found lower pain scores within 90 minutes in the
femoral nerve block group. The incidence of infections was the same in both groups, and there
were no reports of paresthesias [87]. In fact, the total amount of morphine required to produce
adequate analgesia was up to three times higher in intravenous narcotics group than in patients
with a peripheral nerve block [88].
The benefits of peripheral nerve blocks have not only been seen in femoral fractures but also
in other traumatic injuries such as hand lacerations, upper extremity fractures, and disloca‐
tions. For reduction of forearm fractures, studies have shown that children have less distress
and pain when a brachial plexus block was performed versus procedural sedation [89].
Furthermore, length of stay in the ED was also significantly reduced when brachial plexus
block was performed with length of stay being reduced almost 3 hours [90]. Similarly, patients
with shoulder dislocation that underwent a brachial plexus block also showed reduction in
ED length of stay, without any increased adverse events or reduction in patient satisfaction
[91].
One of the most concerning complications of peripheral nerve blocks is nerve damage. In a
peripheral nerve block, the goal is to position the local anesthetic around the nerve and not
“into” the nerve. One should avoid intra-neural injection that may cause direct trauma or
toxicity to the nerve. The incidence of nerve damage in the days following the block (including
temporary paresthesias) ranges from 0.5 to 15% [92, 93]. However, in significant nerve damage
resulting in peripheral neuropathy or symptoms lasting longer than 6 months, incidence was
reported to be less than 0.1% in a prospective study [92, 94]. Most complications of nerve
damage are transient, with most patients recovering by 3 weeks. Localized infection has been
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noted to be rare, with 3% of peripheral nerve catheters in anesthesia studies showing signs of
infection or abscess formation [95]. On the contrary, vascular puncture is not uncommon, and
incidences of up to 5.7% and 6.6% have been noted when investigators placed femoral or sciatic
nerve peripheral catheters [92, 96]. Systemic toxicity, such as cardiac arrest, was found to be
rare, with all cases of cardiac arrest noted to be in central spinal anesthesia. Additionally,
seizures were noted in 6 out of 50,223 cases [94].
Ultrasound and nerve stimulator techniques have been shown to reduce the complications
from peripheral nerve blocks. One study investigating the use of ultrasound or electrical
stimulation in the placement of a brachial plexus peripheral nerve catheter resulted not only
in decreased time performing the procedure but also no vascular punctures in the ultrasound-
guided group [97]. Furthermore, a Cochrane systematic review also confirmed faster proce‐
dure times and reduced local anesthetic volume and improved quality of nerve block [98].
Emergency physicians are adept at using ultrasound in central line placement, as well as in
other diagnostic procedures, such as in FAST abdominal examinations, in trauma patients.
Emergency physicians can be trained in ultrasound-guided peripheral nerve blocks as well.
Ultrasound imaging permits direct visualization of needle location relative to target nerves,
blood vessels, and related structures, as well as observation of the local anesthetic during and
after the injection. A prospective observational study trained emergency physicians in the use
of ultrasound guided peripheral nerve blocks in patients with traumatic limb emergencies and
found that trained physicians were able to perform the ultrasound-guided nerve blocks in
about 9 minutes with no complications and no need of rescue procedural sedation [99].
Prior to the decision to perform a peripheral nerve block, a careful medical history should be
obtained including allergies, use of anticoagulants, preexisting nerve damage, active infections
at the site, and ability to cooperate with the procedures. During the placement of peripheral
nerve bocks, patients should be carefully monitored. It is important to assess for preexisting
sensory or motor deficits in the distribution of the block. A patient with neurologic deficits
prior to the nerve block may be at higher risk for developing new neurologic deficits following
a nerve block than a patient without preexisting deficits. A brief overview of the femoral and
brachial plexus peripheral nerve will be explained in the section below.
3.4. Femoral nerve block
The femoral nerve block is used to anesthetize the hip, anterior thigh, and knee. This nerve
passes beneath the inguinal ligament and travels lateral to the femoral artery within the
femoral triangle (Figure 1) [100]. The fascia iliaca separates the femoral nerve from the femoral
vascular bundle [101]. The patient is initially positioned in a supine position. The affected
extremity is then externally rotated and abducted. With the probe marker to the patient’s right,
a linear probe is then placed at the inguinal crease parallel to the inguinal ligament, the femoral
nerve will then be visualized (it may appear as a hyper echoic, honeycombed structure).
Medially, the femoral artery and then the femoral vein will be present. The iliopsoas muscle
will be present posteriorly and the fascia lata superiorly (Figure 2) [101, 102].
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Figure 1. Femoral triangle.
Figure 2. Placement of the ultrasound linear probe for the femoral nerve block. The patient is laid in a supine position
with the affected extremity externally rotated and abducted. The linear probe is placed in a transverse fashion inferior‐
ly to the inguinal crease.
Once the structures and anatomical landmarks mentioned above have been identified, aseptic
skin preparation is performed and anatomic structures at the block site are again identified
using an ultrasound probe in a sterile plastic sheath with sterile conductive gel (Figure 3). The
structures are once again confirmed on ultrasound and then a skin wheal is made with local
anesthetic. When the optimal ultrasound view is achieved, the probe is held immobile; the
Acute Pain Management in the Emergency Department
http://dx.doi.org/10.5772/62861
13
block needle is then inserted at the skin on the lateral edge of the probe in-plane, aiming for
the space behind the nerve. It is then advanced, with movement only when the needle tip is
seen. Often a “pop” will be felt as the fascia iliaca is penetrated with the needle. Next, aspiration
of the needle is done to confirm no vascular penetration. About 1–2 ml of local anesthetic is
injected to visualize the placement of the needle on the ultrasound screen. The anesthetic
should be seen surrounding the nerve. Once correct placement is confirmed, 10–20 ml of the
selected anesthetic is injected. It may take up to 10–20 minutes to take effect [101–103].
Figure 3. Ultrasound view of the femoral nerve. FA, femoral artery; FV, femoral vein; FN, femoral nerve.
3.5. Brachial plexus block
The brachial plexus block, or interscalene block, can be used to facilitate reduction of upper
extremity fractures, lacerations, and even reduce shoulder dislocations. Nerve roots of C5-T1
are the initial part of the brachial plexus, forming a complex configuration before they enter
the terminal nerves of the arm (Figure 4) [104]. The more proximal one blocks to the plexus,
the more proximal the anesthesia is on the arm. Nerve roots of C5-T1 form the superior, middle,
and inferior trunks of the plexus at the level of the cricoid cartilage. At this location, the plexus
is found superior and posterior to the subclavian artery, with the dome of the lung located
anteromedial to the inferior trunk. The interscalene space is the grove between the anterior
and middle scalene muscles. This is where one will find the structures mentioned above.
However, since the inferior trunk is often not included in this block, one cannot use this
procedure for injuries below the elbow [105].
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Figure 4. Brachial plexus.
Figure 5. Placement of the ultrasound linear probe for the interscalene brachial plexus block. The patient is laid in a
supine position with head turned away. The probe is then placed in a transverse fashion and used to identify the ster‐
nocleidomastoid muscle first. Next, one then sweeps posterior laterally to bring into view the interscalene groove.
The patient is initially positioned supine with the head turned 45 degrees to the contralateral
side. With a linear probe, one first identifies the sternocleidomastoid muscle (SCM), which is
located anteriorly to the carotid artery and internal jugular vein. One then sweeps posterior
laterally bringing into view the middle scalene muscle and anterior scalene muscles. This is
where the trunks of the brachial plexus may be visualized between the anterior and middle
interscalene muscles. As with peripheral nerves, these trunks may appear as hyper echoic
honeycombed structures (Figure 5) [105, 106]. Once the structures are identified, aseptic skin
preparation is performed and anatomic structures at the block site are again identified using
an ultrasound probe in a sterile plastic sheath with sterile conductive gel. A skin wheal is made
using local anesthetic. Then, in an in-plane approach, the block needle is inserted posterior-
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laterally to the probe, at an angle of 45 degrees to the skin. The needle is advanced toward the
plexus, aiming toward the space between the top and middle trunks. Next, aspiration is done
to check for any vascular puncture, and then placement is confirmed with movement of the
trunks on injection of anesthetic. Depending on the agent used, the volume of local anesthetic
is about 15–45 ml (Figure 6) [105, 106].
A second approach to the brachial plexus block is a supraclavicular block. To perform this
block, the patient is once again laid in a supine position with the head turned away from the
side being blocked. A linear probe transducer is then placed immediately superior to the
clavicle at its midpoint (Figure 7). Tilting the probe caudally will bring into view a transverse
view of the subclavian artery. Laterally to the artery, one will be able to see a collection of hypo
echoic, honeycombed structures, which is the brachial plexus. Underneath these structures,
the first rib is visible as a linear hyper echoic structure with lung underneath (Figure 8) [107,
108]. After the correct anatomy is identified, the skin is prepped in a sterile manner, and using
a sterile probe cover, this area is once again identified. A 27-gauge needle is then used to inject
the skin with 1–2 ml of local anesthetic just lateral to the probe. The block needle, 22-gauge, is
then advanced in an in-plane approach toward the brachial plexus from a lateral to medial
direction. At times one may feel a “pop” once the brachial sheath has been penetrated. One
then aspirates to confirm non-vascular penetration and injects 1–2 ml of anesthetic to view the
brachial plexus. Next, one then injects about 20–25 ml of anesthetic, until adequate spread is
seen surrounding the brachial plexus [107].
Figure 6. Interscalene view of the brachial plexus. ISG, interscalene groove with the brachial plexus present; SCM, ster‐
nocleidomastoid muscle; ASM, anterior scalene muscle; MSM, middle scalene muscle.
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Figure 7. Placement of the ultrasound linear probe for the supraclavicular brachial plexus block. The patient is placed
in a supine position or slightly seated position. The linear probe is then placed immediately superior to the clavicle at
its midpoint. Tilting the probe caudally will bring into view the subclavian artery with the brachial plexus seen lateral
to it, and the first rib and lung underneath.
Figure 8. Supraclavicular view of the brachial plexus. SA, subclavian artery; BP, brachial plexus; MSM, middle scalene
muscle.
Peripheral nerve blocks are a valuable asset to the emergency physician trained in these
procedures. These procedures reduce pain quicker than intravenous narcotics, decrease the
amount of sedation needed, and decrease ED length of stays. Peripheral nerve blocks may offer
an alternative to avoid respiratory and cardiovascular depression encountered with
procedural sedation or intravenous narcotics.




Pain is the most common presenting complaint to the emergency room. Appropriate treatment
affects not only patient satisfaction and well-being but also patient outcomes. The choice of an
appropriate initial therapeutic strategy is dependent upon an accurate evaluation of the cause
of the pain and the type of pain syndrome. Effective management of acute pain in the ED
requires a systematic approach. First, an accurate assessment of the patient’s pain should
involve the use of validated pain scales. Second, suitable analgesics given in an acceptable time
frame are essential in the diagnosis and treatment. This should include proper monitoring for
adverse side effects. Third, pain should be reassessed and documented regularly to determine
the effect of treatment.
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Abstract
Injuries in children reach epidemic proportions worldwide as they are the most common
cause of death among children above 1 year of age. It is a well-known fact that first aid
properly administered to the child with severe bodily injuries can save his or her life. That
objective was pursued through a prospective analysis of data concerning the manage‐
ment of children who presented with an injury to the Paediatric Emergency Medicine
Teaching Department at the Maria Konopnicka University Teaching Hospital No. 4, to
which they were brought by emergency medical service teams or referred by a primary
care physician, physicians from other hospitals or a school nurse. The study enrolled all
children (1493) aged 0–18 years who, due to an injury, presented to the Paediatric
Emergency Medicine Teaching Department and had had prehospital aid administered
by different healthcare entities. In the group of 489 children with an injury, in whom there
were indications for the administration of analgesics, only 32.8% received analgesics,
while 45.6% did not receive any. In children with an injury, there was no transport
immobilisation in 18%. Among children provided with transport immobilisation, 10.2%
were improperly immobilised. The management of the child with an injury in the Łódzkie
region is unsatisfactory.
Keywords: children, injuries, prehospital aid, analgesia, transport immobilisation
1. Introduction
For many years now, injuries in children have invariably constituted a serious medical as well
as economic and social problem worldwide, as they are the most common cause of death in
children above 1 year of age. Every year hundreds or even thousands of children die due to
injuries and part of them suffer the irreversible consequences of sustained injuries, which
prevent them from functioning in daily life. According to the World Health Organisation
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
(WHO), traffic accidents (22% of all unintentional injuries in the world) and violence are
among main causes of deaths of young people below 18 years of age. The WHO data of 2008
indicate  that  about  950,000 children and adolescents  die  annually  as  a  result  of  injuries
throughout the world. What is more, it is estimated that 90% of those children lose their lives
due to random accidents [1–5]. It is worth mentioning that a large majority of random injuries
occur at home or in family environment; hence, a place which should ensure safety to the child.
And although world organisations  have implemented various  prophylactic  programmes
aimed at decreasing the incidence of injuries among children (parents’ education, introduc‐
ing the duty to transport children in car safety seats and wear helmets for head protection
while doing different sports), injuries in children remain a worldwide epidemic.
1.1 Injuries in children in the European Union
Paediatric injuries constitute a serious health problem in the European Union countries.
Injuries are the most commonly sustained by children >5 years of age [6–8]. That is confirmed
by Austrian researchers’ observations which reveal that children above 5 years of age ac‐
counted for more than 50% of children with injuries, whereas children aged 1–4 years repre‐
sented 28.4% and those below 1 year of age – 14% of the study group [9]. The incidence of
injuries in children in Poland is not precisely determined due to the lack of the national register
of paediatric injuries. According to Okłot and colleagues [6], in the 1990s about 120,000 children
and adolescents were annually hospitalised as a result of injuries, including 80,000 children
aged 0–14 years. Epidemiological analyses performed in consecutive years suggest a further
increase in the incidence of paediatric injuries.
Boys incur injuries much more often than girls [8–12]. There was a relationship observed
between sex and causes of injuries in the group of children who sustained injuries. According
to the WHO, boys more commonly than girls suffer injuries owing to traffic accidents,
drownings, falls and poisonings, whereas girls more often than boys sustain injuries due to
burns [1].
Children most commonly incur injuries as a result of traffic accidents, drownings, burns, falls
and other causes [13].
In Europe, as in the United States, traffic accidents are the main cause of deaths among children.
The study by Pearson and colleagues of Glasgow indicates that main causes of deaths in the
group of studied children included traffic accidents with participation of pedestrians, followed
by asphyxia, assaults, burns and falls [12].
Paediatric injuries most commonly lead to traumas to the osteoarticular system and head. As
common in children are burns. Recent years’ studies reveal a further rise in the number of
fractures within the osteoarticular system with a simultaneous fall in the number of cranio‐
cerebral injuries [9–11].
Mortality rates from injuries among children vary considerably, from the highest in Lithuania
and Latvia (21.9–22.4 per 100,000) to the lowest in Sweden and the Netherlands (5.8 per
100,000), the main cause of deaths in the group of children aged 10–19 years being random
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accidents [1, 2]. Although observations by Finnish researchers indicate a further increase in
the number of injuries in children, they simultaneously show a decrease in the mortality rate
(4.0 per 100,000 of children up to 18 years of age in 2006) [11]. In Poland, children’s mortality
from injuries is high and the mortality rate due to accidents among children and adolescents
aged 1–14 years of age is about 13.4 [14]. Epidemiological research carried out in the European
Union area revealed that adolescents >15 years of age and small children up to 4 years of age
bear the highest risk of mortality from injuries [2, 6, 15, 16]. As indicated by the European
report on injury prevention in children, if the EU countries achieved the mortality rate from
injuries in children similar to the rates in Sweden and the Netherlands, it would allow to reduce
fatal consequences of injuries by 75% [7].
1.2. Prehospital management of the child with an injury
The proper administration of aid to the child with an injury requires the knowledge of the
child’ anatomical and physiological differences, ability to establish contact with the injured
child and his/her parents/guardians, knowledge of the proper traumatic examination and
interpretation of its results, as well as having at one’s disposal equipment appropriate for the
child.
The general protocol of managing the child with an injury is similar to that applied in adults.
Upon securing the scene of the incident and initial determination of accident circumstances,
the preliminary assessment of the child’s condition is performed according to the International
Trauma Life Support (ITLS) quick injury examination protocol. It is recommended that the
systematic quick assessment of the child with an injury be performed according to the AcBCDE
protocol, which allows to recognise life-threatening conditions within a few minutes.
When approaching the child, his or her general condition is assesses based on ‘the first
impression’, that is conscious state according to the AVPU scale, patency of airways and
manner of respiration, apparent injuries or bleeding. The assessment of airways is performed
along with the stabilisation of the cervical spine. If airways are obstructed or their patency is
threatened with the presence of foreign bodies, blood or vomit, they should be sucked out and
the patency of airways should be restored manually or using devices. The cervical spine can
be stabilised manually but ultimately a cervical collar of an appropriate size and subsequently
a paediatric spinal board or Pedi-Pack should be used. Before applying the collar, attention
should be paid to the widening of jugular veins, position of the trachea and possible wounds
to the neck. When assessing the child’s breathing, the respiratory rate and volume, the presence
of respiratory effort and cyanosis should be checked. In the case of any respiratory difficulty,
passive oxygen therapy or ventilation using a bag valve mask with a reservoir filled with pure
oxygen are necessary. If tension pneumothorax is recognised, it should be decompressed as
quickly as possible by puncturing the second intercostal space in the mid-clavicular line. All
open chest wounds should be protected with a seal dressing [17].
When assessing the circulatory system function in the child, the first step is to secure possible
external bleeding with a pressure dressing. It should be kept in mind that in the small child
compensatory mechanisms allow to maintain normal systemic blood pressure in the event of
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loss of even up to 25% of circulating blood volume. Tachycardia and hypokinetic pulse in the
child are the most definite signs of developing shock. Decreased arterial blood pressure is a
late sign. When hypovolemic shock is recognised, it is essential to use intravenous fluids in
order to compensate for lost blood volume by administering fluids in boluses (initial bolus is
20 ml/kg of body weight of isotonic crystalloids). In children with decompensated circulatory
failure, when intravenous access is difficult to provide, intraosseous access should be consid‐
ered (if attempts at providing intravenous access last more than 1 min) [6, 17–19].
The neurological assessment of the child includes the assessment of pupil widths and the
evaluation of conscious state according to the Glasgow Coma Scale.
Upon performing the above actions, the next step is the quick injury examination (ITLS) of the
child, paying attention to bleedings, fractures or other signs proving the sustained injury.
According to standards, ITLS examination is performed from the head to feet, commencing
from head and neck examination, subsequently examining the chest, abdomen, pelvis, upper
and lower extremities. The child’s back and buttocks are examined while transferring the child
onto the board [6, 18, 19].
Prehospital aid in the case of the child with burns always consists in isolating the child from
the burning agent (through undressing, removing wet or burnt clothes) with the simultaneous
assessment of the child’s basic vital functions. Thereafter, the extensiveness and depth of the
burn wound is assessed along with its simultaneous cooling (using wet compresses). After a
dozen or so minutes of cooling, the burn wound should be provided with sterile or hydrogel
dressing. It is important to protect the child from hypothermia (covering with a blanket) and
commence pain and shock-controlling management [20, 21].
In turn, various kinds of equipment are used to immobilise injuries to upper or lower extrem‐
ities in children. The most commonly used splints are as follows: Kramer’s, Sam Splint, vacuum
splints. In a suspected extremity fracture, immobilisation is vital as it fulfils the following
functions: analgesic, anti-inflammatory and anti-oedematous and protects against the further
displacement of fragments and damage to soft tissues. In order for immobilisation to perform
the above-mentioned functions, it has to be properly applied. Transport immobilisation should
be well adjusted to the child’s size and properly secured with bandage. It should cover the
injured extremity to an appropriate extent (according to Pott’s principle) [22].
Pain is always a consequence of an injury and its intensity depends on the extensiveness,
severity and location of the injury. Increasing pain may lead to pain shock; hence, pain
management is among the most crucial actions when administering aid to the child with an
injury. Pain management is carried out non-pharmacologically, for example cooling the
injured site or immobilisation of fractures, or pharmacologically.
In the case of mild pain, analgesic medicines should be administered as follows: ibuprofen 10
mg/kg of body weight every 6–8 h or paracetamol 10–15 mg/kg of body weight every 4–6 h
orally or per rectum; maximum dose is 60 mg/kg of body weight/day. When pain is severe and
IV access has been provided, analgesics ought to be administered intravenously: morphine
0.1–0.2 mg/kg of body weight or petydyna 1 mg/kg of body weight, fentanyl 1–5 mg/kg of
body weight or metamizole 0.1 ml/kg of body weight [23, 24].
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2. Assessment of medical services provided to the child with an injury
The quality of prehospital medical aid administered to the child with an injury radically affects
his or her further prognosis. Nevertheless, our own observations and literature data indicate
many irregularities in procedures in the prehospital period. The irregularities most commonly
concern the manner of transport immobilisation, lack of IV access provision, pain management
in children with burns or injuries of the osteoarticular system [25–27].
Multicentre studies assessing prehospital pain management in the child with an injury
revealed that the percentage of injured children who did not undergo pain management by
emergency medical service teams ranged from 22 to 70% [28, 29].
The American Academy of Pediatrics together with the American Pain Society report that main
barriers to administering analgesics in children include as follows: the myth that newborns
and infants feel milder pain, lack of appropriate assessment of the presence of pain, lack of
knowledge of pain management and fear of side effects of analgesia including, in particular,
respiratory system depression [23].
Along with studies indicating the abandonment of pain management in children with an
injury, there are also isolated reports of irregularities in fracture immobilisation in children
[30].
Although mistakes and oversights in the prehospital management of the child with an injury
are the subject of deliberations, especially related to emergency medical service teams, the
literature offers no evaluation of that management carried out by other healthcare entities.
Therefore, based on their own experience, the authors of the present study have undertaken
the task of assessing the (prehospital) management of the child with an injury by different
healthcare entities taking into account the manner of wound and burn dressing in children,
the manner of management of fractures and dislocations within the osteoarticular system, the
provision of intravenous access and pain management.
The study enrolled 1493 out of 7146 children aged 0–18 years who due to an injury presented
to the Department of Paediatric Emergency Medicine (Hospital Emergency Department) at
Maria Konopnicka Memorial University Teaching Hospital No. 4 from 1 May 2009 to 30 April
2010 and had received prehospital aid provided by emergency medical service teams (EMST),
primary care (PC) physicians, hospital emergency departments for adults in the Łódzkie region
and school nurses (Figure 1).
It was a prospective study which, in each child with an injury, along with demographic data,
investigated information concerning: the cause, circumstances and site of the wound, entity
administering medical aid, assessment of pain management, regularity of transport immobi‐
lisation, assessment of local wound and burn dressing, and assessment of medical records
transferred to the Department with the child. The study used a child with injury card devel‐
oped for the purposes of the study, which allowed to perform the above assessments in a
uniform manner. The child with injury card was worked out based on the literature on the
aetiology of paediatric injuries [26, 31, 32].
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Figure 1. Poland compared to the rest of the world.
Every card was entered in the database created by us in the Excel program and statistically
processed. The collected data underwent statistical analysis for measurable and non-measur‐
able traits. Qualitative traits were also analysed by calculating structure ratios. In the statistical
analysis of empirical data, the following tests were used to verify hypotheses on the inde‐
pendence of two qualitative traits in the population: Pearson’s χ2 significance test for qualita‐
tive variables and χ2 test with Yates’ correction.
Children with an injury accounted for 30.6% of patients from the territory of the Łódzkie region
who presented to the Department of Paediatric Emergency Medicine at Maria Konopnicka
Memorial University Teaching Hospital No. 4 in Łódź over the year.
Boys decidedly predominated among the injured (60.3%), p < 0.001.
Almost 80% of children with an injury were those >5 years of age. No relationship was observed
between the child’s sex and age, p > 0.05.
Prehospital medical aid was the most commonly administered to children by emergency
medical service teams (42.7%), less often by a PC physician (28.1%) and other hospitals (23%),
and the least commonly by a school nurse (6.1%).
In the study group, children with an injury most often necessitated out-patient treatment
(67.1%).
Among children who sustained an injury, traumas to the head (42.1%), upper extremities
(32.2%) and lower extremities (19.9%) were noted. Injuries to the abdomen (2.5%), spine (2.1%),
chest (1.7%) and neck (1.1%) were less often observed.
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In children with a head injury, superficial traumas to the head predominated (53.3%), head
wounds (24.3%) and concussions (20.3%) were less common, and fractures of the cranial bones
(2.1%) were the least common.
As for children with other bodily injuries, blunt traumas to the neck, superficial chest, abdomen
and spine injuries predominated.
Among children in whom upper extremity injuries were observed, traumas to the forearm
were the most (42.7%) and to the carporadial joint the least (1.3%) common.
In the group of children with injuries to the lower extremity, ankle joint traumas (26.2%) were
the most and traumas within the pelvis, hip joint and kneecap were the least often (1.7%) found.
Burns were the reason for presenting to the Department for 79 out of 1493 patients, which
accounted for 5.3% of all children. They were the most often caused by a thermal factor (77
patients), while a chemical burn was found in 1 and an electric burn in 1 child, respectively.
In the group of 1493 children administered first medical aid by different healthcare entities
indications for pain management were found in 489 children (32.75%).
Among children who required analgesia, only 159 children (32%) received analgesics, while
223 children (46%) did not receive any and there was no information about analgesia in medical
records of 107 patients (22%) (Figure 2).
Figure 2. Provision of analgesics in children who sustained injuries.
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92 44.44 6 40.00 47 49.47 78 45.35
Analgesics
administered




11 5.31 1 6.67 33 34.74 62 36.05
Total 207 100.00 15 100.00 95 100.00 172 100.00
Statistical
analysis
chi2Pearson test = 87.33 p < 0.001; chi2MV test = 96.30 p < 0.001
Note: statistical analysis did not consider the school nurse.
Table 1. Pain management in the study group.
The performed statistical analysis indicates that all the examined healthcare entities failed to
administer analgesics in over 40% of cases (due to their scarce number, patients managed by
school nurses were not taken into account). The lack of information about the administration
of analgesics in the patient transfer card is also a matter of concern. That was significantly more
common in children referred for treatment by a PC physician (34.7%) and patients referred by
other hospitals (36%), p < 0.001, while that was the least common in children brought to the
Department by emergency medical service teams (5.3%)—chi-squarePearson test = 87.33 p < 0.001;
chi-squaredMV test = 96.30 p < 0.001 (Table 1).
Among children who did not receive analgesics, children with upper extremity fractures—92
cases (41%) and lower extremity fractures—21 cases (9%) predominated. Detailed
characteristics of injuries in children who were not provided with analgesics (despite
indications) are presented in Table 2.
Location of injuries Injury, contusion Wound Fracture Dislocation Sprain Burn
Head 18 14 1 0 0 2
Neck 2 1 0 0 0 0
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Location of injuries Injury, contusion Wound Fracture Dislocation Sprain Burn
Chest 3 0 0 0 0 4
Spine 2 0 2 0 0 0
Abdomen 3 0 0 0 0 1
Upper extremity 14 7 92 5 0 3
Lower extremity 8 11 21 1 4 4
Table 2. Characteristics of injuries in children who were not provided with analgesics n = 223.
In the group of 1493 children administered first medical aid by different healthcare entities
transport immobilisation of sustained osteoarticular system injuries was required by 614
children (41.1%). 383 children (62.4%) were properly immobilised for transport, whereas 110
children (17.9%) presented to the Department with no transport immobilisation of fractures,
dislocations or sprains. In 121 cases (19.7%), there was no information about applied transport
immobilisation in the patient transfer card (Figure 3).
Figure 3. Application of transport immobilisation in children with injury.
Among 383 children immobilised for transport, 261 children (68.1%) were properly and 39
children (10.2%) improperly immobilised. In 83 children (21.7%), it was impossible to
determine the quality of applied immobilisation (Table 3).




























179 72.18 60 84.51 49 39.84 95 55.23
No transport
immobilisation




21 8.47 1 1.41 42 34.14 57 33.14
Total 248 100.00 71 100.00 123 100.00 172 100.00
Statistical analysis chi2Pearson test = 61.92 p<0.001; chi2MV test = 66.81 p<0.001
Note: statistical analysis did not consider the school nurse.
Table 3. Healthcare entity and osteoarticular system immobilisation.
The regularity of transport immobilisation applied in the studied group of children was































18 10.06 4 6.66 5 10.21 12 12.63
Appraisal
impossible
35 19.55 5 8.34 14 28.57 29 30.53
Total 179 100.00 60 100.00 49 100.00 95 100.00
Statistical analysis chi2Pearson test = 41.14 p < 0.001; chi2 MV test = 42.11 p < 0.001
Note: statistical analysis did not consider the school nurse.
Table 4. Healthcare entity and regularity of osteoarticular system immobilisation.
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The carried out statistical analysis, which due to their scarce number did not take into account
patients managed by school nurses, indicated that transport immobilisation in children who
required that was most commonly applied by emergency medical service teams, followed by
hospital emergency departments/emergency rooms of other hospitals and PC physicians.
Those observations were statistically confirmed: chi-squaredPearson test = 61.92 p < 0.001; chi-
squaredMV test = 66.81 p < 0.001.
It should also be noted that transport immobilisation was abandoned by emergency medical
service teams in about 20%, by PC physicians in over 26% and by other hospitals in about 11%
of cases.
Transport immobilisation was significantly more often properly applied by emergency
medical service teams (70.4%) and PC physician (61.2%). On the other hand, only half of the
patients from other hospitals presented to the Department properly immobilised (56.9%).
Those observations were statistically confirmed: chi-squaredPearson test = 41.14 p < 0.001; chi-
squaredMV test = 42.11 p < 0.001.
It is worth noticing that in the case of one-third children referred to the Department by a PC
physician or from other hospitals there was no information about applied transport immobi‐
lisation in medical records. It should also be noted that there was no information about the
regularity of transport immobilisation in patients transferred by other healthcare entities in
almost 30% of cases, while it was known that children had had transport immobilisation
applied as such a note had been made in the patient transfer card (Tables 3 and 4).
Among children who were not immobilised for their transport to the Department, children
with upper extremity fractures—33 cases (30%) and lower extremity fractures—14 cases
(12.7%) predominated. Children with contusions of various regions of the body—41 cases
(37.2%) and sprains within the ankle joint—13 children (11.8%) were also referred to the
Department. Detailed characteristics of injuries in children without transport immobilisation
are shown in Table 5.
Location of injuries Injury, contusion Wound Fracture Dislocation Sprain
Head 12 0 3 0 0
Neck 0 0 0 0 0
Chest 2 0 0 0 0
Spine 2 0 2 0 0
Abdomen 3 0 0 0 0
Upper extremity 9 2 33 0 0
Lower extremity 13 0 14 2 13
Table 5. Characteristics of injuries in children without transport immobilisation n = 110.
Examples of improper transport immobilisation in children who presented to the Department
referred by different healthcare entities are shown in Figures 4 and 5.
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Figure 4. Transport immobilisation in a boy with displaced fractures of both forearm bones.
Figure 5. Transport immobilisation in a girl with a humeral bone fracture—bandage fixing the splint to the arm ends at
the height of the fracture crevice.
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Among 1493 children who were prehospitally managed by different healthcare entities, the
integrity of the skin was breached due to an injury in 372 children (24.9%). The medical
management of wounds, abrasions or burns in children with an injury is shown in Figure 6.
Among children not provided with dressing, children with head traumas—15 cases (45%),
upper and lower extremity injuries—6 children (18.2%) and burns of different body regions—
12 children (36%) predominated.
Figure 6. Medical management of wounds, abrasions and burns in the study group.
Among 281 children with dressed integumentary traumas, dressing was properly applied in
260 cases (92.5%), improperly applied dressing was observed in 5 children (1.8%), while no

























174 82.86 10 100.00 42 55.26 55 72.37




20 9.52 0 0.00 21 27.63 17 22.37
Total 210 100.00 10 100.00 76 100.00 76 100.00



























chi2Pearson test = 26.67 p < 0.001; chi2MV test = 25.75 p < 0.001
Note: statistical analysis did not consider the school nurse.
Table 6. Analysis of wound management regularity depending on the healthcare entity.
The regularity of dressing applied in the studied group of children was analysed taking into































1 0.57 0 0.00 2 4.76 2 3.64
Appraisal
impossible
7 4.03 0 0.00 3 7.14 6 10.91
Total 174 100.00 10 100.00 42 100.00 55 100.00
Statistical
analysis
chi-squaredPearson test = 23.15 p < 0.001; chi-squaredMV test = 24.11 p < 0.001
Note: statistical analysis did not consider the school nurse.
Table 7. Analysis of wound management regularity depending on the healthcare entity.
Although the statistical analysis indicated significantly common proper management of
wounds and integumentary injuries, irregularities of that management were observed.
Detailed information is shown in Tables 6 and 7.
In the study group, 124 out of 1493 children (8.3%) necessitated prehospital IV access provision
for the intravenous administration of medications or fluids. Among those 124 children, a
majority—116 (93.5%) patients—were provided with a peripheral venous catheter, while IV
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access was not provided in 5 children (4%), and there was no information about IV access in
the patient transfer card in 3 children. Among children provided with IV access, irregularities
were observed in 2 cases. They consisted in placing a peripheral venous catheter on the
fractured extremity in one case and improper securing of IV access in the other (Figure 7).
Figure 7. Provision of IV access in the studied population.
Prehospital aid properly administered to the child with an injury significantly affects the
prognosis and fate of the patient. Therefore, the knowledge of the rules of management and
administration of first aid to the child with bodily injuries is essential to every physician, nurse
and paramedic working in the emergency medical service system and primary healthcare.
Own experience and data from the world literature indicate that prehospital medical aid
administered to the child with an injury is not always proper. Irregularities most often concern
the manner of transport immobilisation and pain management in children with fractures
within the osteoarticular system and in children with burns [25, 33, 34]. Main barriers limiting
the administration of analgesics (morphine) to children with an injury include difficulty with
pain severity assessment in the child, lack of the patient’s/legal guardian’s consent to receiving
analgesics and difficulty with providing IV access [25–27].
Our own study evaluating the manner of administering prehospital aid to the child with an
injury by different healthcare entities was based on the observation of 1493 cases.
Boys significantly predominated girls in the study group. The male to female ratio among
children was 1.52:1, p < 0.001. Similar observations were made by other authors unanimously
emphasising that the higher incidence of injuries in boys arises from their increased cognitive
activity [5, 13, 35].
The age in the study group ranged from 1 day to 18 years (the median age was 11.4 years, and
the mean age was 11.2 years). It was noted that, similarly to other studies in Poland and the
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world, over 50% of injuries occurred in children aged 5–14 years, p < 0.001, which may result
from very intense activity and curiosity about the world as well as children’s lack of ability to
evaluate threatening dangers during play [3, 9, 35].
In the studied group of children prehospital medical aid was most commonly administered
by emergency medical service teams (42.7%) and the least commonly by a school nurse (6%),
although school was often the place where an injury was sustained. The phenomenon stems
from the fact that an emergency medical service team not only administers first medical aid
but also ensures professional transport to a hospital emergency department.
When comparing how the administration of prehospital aid to the child with an injury is
organised in Poland and the world, some similarities can be observed. In the United States and
Canada, when emergency medical service teams are called, prehospital aid is most often
administered by emergency medical technicians of the first and second level, paramedics,
nurses and the least commonly—physicians [36]. In Poland, in emergency medical service
teams, aid is mostly administered by paramedics, and slightly less often—by nurses and
physicians.
Among injuries in the children in the study group head injuries were more often observed
than in studies by other authors (the study group: 42.1% vs. studies of the National Hospital
Ambulatory Medical Care Survey ED files: 23.1%), whereas the incidence of extremity injuries
was similar to observations by other authors. The predominance of head injuries over
extremity injuries observed in our study results from the customary referral of every child with
a head injury to the surgeon by the paediatrician. Also, similarly to reports by other authors,
minor head injuries predominated among injuries [33, 37, 38].
Neck injuries were rarely found in children and those were mainly blunt traumas and
integumentary wounds. Chest and abdominal injuries were slightly more often observed.
Among patients who sustained chest injuries, those were mostly superficial chest injuries, with
chest wounds and rib fractures being less common. Similarly, in children who suffered an
abdominal injury superficial abdominal injuries predominated, while crotch and external
genitals or parenchymatous organs injuries were less often observed.
Damage to the upper and lower extremity was among the most common consequences of
injuries in children. Our own study indicated that, similarly to the study by Erik M. Hedstrom
of Sweden, the most common fracture within the upper extremity was the fracture of the
forearm bones, whereas the fracture of the femoral bone shaft was the most common lower
extremity injury [3, 15, 38].
The analysis of the management of children with an injury by different healthcare entities
showed that a majority of children (72%) were properly administered prehospital medical aid.
However, some oversights were found in medical management concerning the administration
of analgesics, lack or irregularities of applied transport immobilisation and irregularities in
the dressing of integumentary injuries.
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Main irregularities observed in ‘post-traumatic’ children included the lack of the appropriate
pain management of children with an injury. As indicated by our own study, pain relief efforts
were made in merely 32.5% of children with indications for pain management. Almost a half
of patients (45.6%) did not receive any analgesics despite indications. Among children who
did not receive analgesics, children with upper extremity fractures (41%) and lower extremity
fractures (9.5%) predominated. Similarly to the study by Rawlins [39], we noted the lack of
pain management in 6.3% of children with burns. According to the American Academy of
Pediatrics and American Pain Society, main barriers to managing pain in children include as
follows: the myth that newborns and children feel milder pain than adults, lack of appropriate
assessment of the presence of pain, lack of knowledge of pain management and fear of side
effects of analgesia (particularly respiratory system depression) [23, 24, 26]. It arises from the
study performed by physicians of the paediatric emergency department in Auckland that the
fear of causing to the child pain connected with injection resulted in the lack of administration
of analgesics [28]. Similar observations were made by the Toronto team [36]. Researchers from
the United States also noted that abandoning the administration of analgesics was not
associated with the specialty of physician providing aid [26].
Another reservation as to the management of children with an injury regarded the transport
immobilisation of children with osteoarticular system injuries. The world and Polish literature
offers few studies dedicated to that issue [29, 30]. Out of 614 children requiring transport
immobilisation, immobilisation was applied in only 62.4% of cases, out of which in 90%
properly. On the other hand, 17.9% of the injured children presented to the Department with
no transport immobilisation of fractures, dislocations or sprains, while in 19.7% of cases, there
was no information about applied transport immobilisation in the patient transfer card.
Among children with improperly applied transport immobilisation, the irregularity of
immobilisation concerned the extent of immobilisation and sloppy securing of the transport
splint on the injured extremity.
The irregularity of applied transport immobilisation was observed mainly in children with
fractures within the osteoarticular system of the upper extremity. Immobilisation irregularities
were most common in children with forearm bones’ fractures (improper extent), clavicular
fractures (sloppy bandaging of the extremity to the chest), humeral fractures (improper extent)
and within the hand (2 children—incorrect securing with bandage). Irregularities were also
observed in children with lower extremity fractures (improper extent, sloppy securing). There
were also cases of improper securing of children after traffic accidents during transport (e.g.
lack of the cervical collar and incorrect laying on the spinal board (only three straps without
side head supports)). The lack of transport immobilisation and its irregularity can be explained
by both the lack of knowledge of the proper extent of injured extremity immobilisation and
lack of awareness of the fact that properly applied transport immobilisation not only protects
against additional injuries but is also a basic method of pain management in the child with an
injury within the osteoarticular system. The child with a properly immobilised injured
extremity suffers less. Sloppiness in applying transport immobilisation may result from the
lack of appreciation of the importance of that medical procedure. During classes, students
think that the proper application of transport immobilisation is a very simple task and are not
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interested enough in that issue. The lack of transport immobilisation may also result from
erroneous consideration that handling the child when applying immobilisation may be painful
to the child. The lack of medical equipment used to immobilise the extremity which is properly
adjusted to the size of the child may also be among reasons behind the lack of the transport
immobilisation of the child.
The manner of the dressing of wounds and burns in the study group was also questionable as
the lack of dressing was found in 8.9% of patients, improper dressing of a wound—in isolated
cases and lack of information about dressing in medical records—in 15.6% of cases.
Irregularities in wound dressing concerned burn wounds.
Oversights in administering prehospital aid to children with an injury and gaps in medical
records concerned all the studied healthcare entities. Observations concerning neglect while
administering first aid to the child with an injury by emergency medical services were
described by other authors too [28].
3. Conclusions
1. The management of the child with an injury in the Łódzkie region is unsatisfactory.
2. Despite the training of physicians, nurses and paramedics in the management of paedi‐
atric injuries, the lack of analgesic provision is still encountered in almost half of the
patients, irregularities in transport immobilisation—in about 10% of the patients and
irregularities in wound management and IV access provision—in isolated cases. In one-
fourth of the cases, gaps in medical records were also noted.
3. The observed irregularities indicate that it is necessary to intensify training related to
medical aid for children after injuries and supplement equipment adjusted to the size of
the child available in emergency medical service teams, primary care physicians’ surgeries
and surgeries at schools.
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Abstract
According to the theory of traditional Chinese medicine, Qi flows through the body along
specific paths known as meridians. Any disturbance in Qi evokes a Ying−Yang imbal‐
ance in the body, and consequently leads to disease. Pain results from blood stasis and Qi
stagnation. Laser acupuncture (LA), first introduced clinically in the 1970s, combines the
advantages of traditional acupuncture and modern laser medicine and has been applied
for the treatment of various diseases. Here, we investigated studies on the use of LA for
pain management according to current evidence. Articles including English keywords
related to the use of LA for pain, published between January 2006 and August 2015 were
sourced from PubMed, Medline, and Cochrane Library databases. On the basis of these
papers, we explored the modern applications, mechanisms, and analgesic effects of LA.
LA integrates the positive effects of acupuncture and low-level laser therapy, and is
therefore effective in activating blood and in moving Qi. LA relieves pain through both
anti-inflammatory and analgesic effects. No adverse effects or complications resulting
from LA were reported in the literature. In the hands of an experienced physician, LA can
be a useful and safe method for pain management.
Keywords: laser acupuncture, low-level laser therapy, acupuncture, pain, traditional
Chinese medicine
1. Introduction
Although written accounts of acupuncture date back over 2000 years, archaeological evi‐
dence suggests more than 3000 years of practice. According to the principles of traditional
Chinese medicine (TCM), energy (or Qi) flows through the body along specific paths known as
meridians. Balanced Qi contributes to the maintenance of good health. On the other hand, any
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
disturbance in Qi results in an energy imbalance in the body. This imbalance, either an excess
or a deficiency, may then result in disease [1]. Both blood stasis and Qi stagnation will lead to
pain [2]. In 1996, the World Health Organization (WHO) confirmed 64 indications for acupunc‐
ture treatment. Acupuncture treats the underlying diseases by stimulating specific acupunc‐
ture points along the meridians. Acupuncture is one of the most common types of alternative
treatments for patients who suffer from long-term pain. Moreover, it is a relatively safe procedure
with minimal adverse effects [3]. Even though acupuncture has been proven to be effective for
many therapeutic applications, metal needling is not widely accepted owing to fear of possi‐
ble contamination or transcutaneous lesions [4]. Consequently, following the theory of TCM,
the use of low-level laser on acupuncture points has been developed as a new therapeutic
approach called laser acupuncture (LA) [5, 6].
LA was first introduced clinically in the 1970s [7]. It has been widely studied over several years
to turn it into an evidence-based clinical practice. The use of low-intensity and nonthermal
laser irradiation stimulation of acupuncture points is an effective alternative to traditional
metal needling; it is a safe technique because it is noninvasive and is acceptable to needle-
phobic persons. Thus, LA can be used at acupuncture points that require complicated appli‐
cations of needles [1, 8]. The laser beam is an electromagnetic wave and can stimulate
acupuncture points in the human body by depositing energy without causing heating. In
contrast to needling, acupuncture points irradiated by a laser beam need to receive sufficient
energy to induce a physiological effect at the cellular level based on the principle of “photo‐
biomodulation.” The beam excites the relevant channels and activities, regulates the function
of organs, and promotes metabolism. Recently, several papers have reported that the decisive
factor in the efficacy of LA is the applied dosage [5, 9–11].
Although the mechanisms underlying LA are not well understood, LA is widely applied
clinically. LA is also referred to as low-level laser therapy (LLLT), with 0.1–0.5 J/cm2 deposited
per acupuncture point, or 1–4 J/cm2 per Ashi point [12]. LLLT has an anti-inflammatory
function because it can reduce the levels of certain biochemical factors (prostaglandin E2,
messenger ribonucleic acid cyclooxygenase-2, interleukin (IL)-1β, and tumor necrosis factor
(TNF)-α), neutrophil influx, oxidative stress, edema, and hemorrhaging [13]. Analgesia
induced by laser phototherapy is mediated by peripheral opioid receptors [14]. Nevertheless,
LA has both local and distant analgesic effects, which may be mediated by different mecha‐
nisms. LA combines the advantages of traditional metal-needle acupuncture and LLLT. This
chapter on managing pain by LA focuses on how LA may be an alternative method of relieving
pain and improving functional outcomes.
2. Review of the clinical literature
Clinical literature in electronic databases—PubMed, Medline, and Cochrane library—was
surveyed using the terms “laser acupuncture”, “low level laser therapy”, and “pain”, pub‐
lished from January 2006 to August 2015. All papers had to meet the following criteria:
randomized controlled trials (RCTs) that considered a control group (either placebo, sham LA,
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nonstandard traditional acupuncture, or other therapeutic equipment) and retrospective/
prospective clinical studies in which LA/LLLT was used. Studies cited in review articles were
also included. Papers published in languages other than English were excluded. Conference
abstracts, single-case studies, and paper for which full text was not available were also
excluded.
Among the reviewed literature, most studies targeted myofascial pain, fibromyalgia, tendin‐
opathy, radiculopathy, osteoarthritis (OA), low back pain, temporomandibular joint dysfunc‐
tion (TMD), and headache. These are discussed below.
2.1. Myofascial pain
Kiralp et al. [15] reported a RCT in which 43 patients with myofascial pain were enrolled, and
showed the positive effect of LA as compared to prilocaine injection. Eight other RCTs also
showed the pain-relieving effect of LA; some of these focused on myofascial pain over the
cervical region [16, 17], masseter [18], masticatory muscles [19, 20], trapezius [21, 22], or trigger
points [23]. The consistency of these trials highlighted the efficacy of LA in the treatment of
myofascial pain.
2.2. Fibromyalgia
Two RCTs showed different results for LA treatment of fibromyalgia [24, 25]. Both of these
studies obtained subjective pain presentation using a visual analog scale (VAS), the Fibro‐
myalgia Impact Questionnaire (FIQ), and other measures. Armagan et al. [24] reported positive
results of LA for treating the pain of fibromyalgia. The difference between these studies was
the dose and power density. Armagan et al. set the parameters of LA to 830 nm, 2 J/point, and
50 mW. These results suggested that the treatment effect of LA was inconclusive in fibromyal‐
gia or that the power density used should be sufficiently high to manage the pain in this disease
group.
2.3. Tendinopathy
Two RCTs showed positive results of LA in pain management of lateral epicondylitis (LE) [26,
27], also known as tennis elbow. Emanet et al. [27] reported that even though LA had no short-
term advantage over the placebo in patients with LE, there was a significant long-term
improvement, especially in functional parameters. Another RCT reported that LA had a
treatment effect equal to that of ultrasound [28]. Moreover, a systemic review revealed that
applying LLLT to myofascial trigger points of LE patients was an effective treatment for pain
reduction and also led to increase in grip force, range of motion (ROM), and weight test [9].
As for tendomyopathy of the masticatory musculature, the pilot study showed inconclusive
results because there were few participants [19].
2.4. Radiculopathy
Konstantinovic et al. [29] performed an RCT that enrolled 60 patients with acute neck pain
with cervical radiculopathy. After a 3-week LA treatment, VAS, neck movement, neck
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disability index, and quality of life indicated the positive effect of LA. Radiculopathy of other
spinal segments was not reported.
2.5. Osteoarthritis
Among the four RCTs on the use of LA in treating the pain of knee OA, two showed a positive
result [30, 31], one was inconclusive [32], and the other one reported efficacy after 2 weeks of
treatment but not at the 4-week assessment [33]. However, the RCT showed the inconclusive
result for only one point, ST35. An inappropriate dose or insufficient irradiation at a point may
be the reason for the poor treatment effect.
2.6. Low back pain
Glazov et al. [34] had reported negative result for the use of LA to relieve low back pain in
their study, in which LA was applied to local points of three meridians (Bladder, Gallbladder,
and Governor vessel) and Ashi points. Subsequently, Glazov [35] reported another RCT, in
which 100 patients with low back pain were enrolled, and found a positive result for pain
management with LA. However, the parameter settings used for the second RCT were not
described. Therefore, we were not able to determine the differences that contributed to the
successful treatment. Nevertheless, further two RCTs showed a positive response for low back
pain treated with LA [36, 37].
2.7 Temporomandibular joint disorder
In our literature search, all four RCTs suggested a positive treatment effect for LA in treating
the pain associated with TMD [4, 38–40]. Occlusal splinting is the nonsurgical standard
treatment for this condition in dental clinics. In two RCTs, LA was found to be as effective as
occlusal splinting in relieving TMD-associated pain [39, 40]. LA could be an alternative
treatment choice to occlusal splinting. Sattayut and Bradley [41] compared low- and high-
grade LA and found that high-grade LA, i.e., 820 nm, 107 J/cm2, and 300 mW, showed a superior
treatment effect. More recently, Hu et al. [42] clearly showed the therapeutic effects of LA in
managing treatment-resistant TMD. In our literature review, another two clinical trials
revealed the benefit of LA therapy for TMD patients [43, 44].
2.8. Headache
Gottschling et al. [45] reported an RCT in which LA was used to treat headache in children
and showed a decrease in the VAS score and monthly hours with headache. Interestingly, the
treatment in this study consisted of only four treatment episodes, at a frequency of once a week,
yet the improvement of symptoms was excellent. This study also focused on the meridian-
based selection of irradiation points. The basic points for patients with frontal headache were
LI4 and ST36; for lateral pain, they were TE6 and GB34; for occipital pain, they were SI3 and
BL60, and for holocephalic pain, it was GV20. Additional body acupuncture points and ear
acupuncture points were chosen individually. The combination of TCM meridian theory with
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LA energy treatment seemed to provide a better effect than simply irradiating the tender
points.
2.9. Others
Chow et al. [17] reported that chronic neck pain of any etiology could be treated successfully
with a program of 14 LA treatments over a period of 7 weeks. Ip and Fu [46] reported a
prospective cohort study that proved the treatment efficacy of LA in painful adhesive capsulitis
of the shoulder.
3. Conclusions
We have presented evidence supporting the use of LA in the management for various types
of pain (Table 1). LA is a noninvasive technique involving the stimulation of traditional
acupuncture points with low-intensity laser irradiation. LA has the advantages of being
painless and safe as no heat is generated during the procedure, and it is more effective in some
medical conditions and requires less time than needle-based acupuncture [47]. No adverse
effects or complications resulting from LA have been reported in any study to date. The
effectiveness of LA in managing pain depends on the selection of appropriate points and
frequencies. Insufficient energy and very few therapeutic sessions will result in ineffective
therapy. In conclusion, LA combines the positive effects of traditional Chinese acupuncture
and LLLT, and is therefore effective in both activating blood and moving Qi. LA relieves pain
through both anti-inflammatory and analgesic effects. As experienced physicians, we should
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DASH: disabilities of the arm, shoulder, and hand; DASS-21: Depression Anxiety Stress Scale; EMG:
electromyography; EQ-5D: Euro-Quality-of-Life Five Dimensions questionnaire; KC: knee circumference; MOSP:
maximum mouth opening (MMO) without pain; MTS: medial tenderness score; NHP: Nottingham Health Profile;
NTP: number of tender points; ODI: Oswestry Disability Index; PGIC: Patient Global Impression of Change; PPT:
pressure pain threshold; PRTEE: Patient-Related Lateral Epicondylitis Evaluation; PWI-A: Personal Wellbeing Index;
SF-36: 36-item Short-Form Health Survey; VPS: verbal pain scale; VSGI: global improvement on a verbal scale;
WOMAC: Western Ontario and McMaster Universities osteoarthritis index.
Table 1. Summary of clinical studies into pain management with laser acupuncture.
Abbreviations
DASH disabilities of the arm, shoulder and hand
DASS-21 Depression Anxiety Stress Scale
EMG electromyography







MOSP maximum mouth opening (MMO) without pain
MTS medial tenderness score
NHP Nottingham Health Profile
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NTP number of tender points
OA osteoarthritis
ODI Oswestry Disability Index
PGIC Patient Global Impression of Change
PPT pressure pain threshold
PRTEE Patient-Related Lateral Epicondylitis Evaluation
PWI-A Personal Wellbeing Index
RCT randomized controlled trial
ROM active range of motion
SF-36 36-item Short-Form Health Survey
SSI symptom severity index
TCM traditional Chinese medicine
TMD temporomandibular joint (TMJ) disorder
VAS visual analogue scale
VPS verbal pain scale
VSGI global improvement on a verbal scale
WHO World Health Organization
WOMAC Western Ontario and McMaster Universities osteoarthritis index
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Abstract
Herpes zoster (HZ) is a disease triggered by the reactivation of latent varicella zoster virus
(VZV) in spinal or cranial sensory ganglia, and is characterized by a painful vesicular
eruption  in  the  affected  dermatome.  Postherpetic  neuralgia  (PHN)  is  a  chronic,
neuropathic pain that can persist long beyond resolution of visible cutaneous manifes‐
tations which is often resistant to current analgesic treatments. The lifetime prevalence
of herpes zoster is approximately 20–30% and about 9–34% of these patients develop PHN
depending on its definition. Clinical experience has shown that PHN often develops in
cases of inadequate initial pain management resulting in increased pain intensity. This
review provides an overview of the treatment options for HZ and PHN, focusing on the
therapeutic modalities of pain management. The primary objectives of management of
HZ are to inhibit viral replication, relieve pain, and prevent associated complications,
such as PHN. General treatments for acute HZ are combination of antiviral therapy with
a short course of corticosteroids at the onset of the disease in conjunction with an effective
control of acute pain, including nonsteroidal anti-inflammatory drugs, acetaminophen,
opioids, and anticonvulsants such as gabapentin or pregabalin. Treatment of PHN is often
resistant to the current pharmacologic methods. Therefore,  a multimodal analgesic
treatment regimen including topical lidocaine and capsaicin, systemic therapies, and the
interventional treatments is necessary to alleviate pain and its effect on quality of life. As
the incidence of HZ increases with age, the number of patients with HZ and PHN may
increase in the future considering the gradual aging of the general population. Appro‐
priate management of HZ can reduce the duration and intensity of pain from HZ, and
prevent the development of PHN. In addition, prophylactic zoster vaccination can prevent
or reduce the incidence of HZ and PHN. Further efforts are needed to minimize pain of
the patients suffering from HZ and PHN as it affects the quality of life in the aspect of both
physical and psychological impairments.
Keywords: Herpes zoster, post-herpetic neuralgia, pain control, treatment of herpes
zoster, management of post-herpetic neuralgia
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus (VZV) in sensory
dorsal root ganglion cells, and is characterized by a painful, unilateral vesicular skin eruption
in the affected dermatome. The lifetime risk of HZ is approximately 15–30% [1–3]. The inci‐
dence of herpes zoster is 1.5–3.0 per 1000 person-years in all ages and 7–11 per 1000 person-
years in persons over 60 years of age in European and North American, according to studies [1–
9]. Classically, the skin eruption is preceded by one to several days of stabbing, episodic or
continuous pain in the affected area, although the pain may develop simultaneously or even
following the skin eruption. Herpes zoster-associated pain tends to resolve over time, but
approximately 10–50% of herpes zoster patients develop post-herpetic neuralgia (PHN) that
can persist several years beyond resolution of visible cutaneous eruptions. The frequency of
PHN has been reported to be from 10% to 50% depending on its definition [10]. PHN is typically
defined as persistent pain 90 days after the acute onset of HZ [3, 11, 12]. The incidence of PHN
by this definition is 10–20% [3, 12]. In approximately 15% of patients with PHN, the pain persists
for up to two years [13]. Mechanism to cause PHN follows a classic paradigm of other forms of
neuropathic pain. Sensitization of nociceptors occurs after inflammation of dorsal root ganglia
by reactivation of varicella zoster virus, leading to hyperexcitability of sensory neurons. The
spontaneous discharge and lower activation thresholds provoke exaggerated responses to
stimuli, resulting in allodynia and hyperalgesia. The loss of function or death of dorsal horn
neurons, contributes to a connectional state of central nervous system nociceptive pathways,
after anatomic deafferentation. The central sensitization is initially temporary, but may become
permanent [14, 15]. Clinical experiences have shown that immunocompromised patients and
elderly individuals are at an increased risk of PHN, and early initiation of antiviral treatment
may reduce the incidence of PHN [16]. This review focuses on the practical overview of the
treatment options available for management of patients with acute HZ and PHN.
2. Treatment of acute herpes zoster
The management of acute HZ aims to inhibit ongoing viral replication and alleviate pain.
Treatment modalities for acute HZ include antiviral agents, analgesics, corticosteroids, and
neural blockade.
2.1. Antiviral agents
Acute HZ is treated with antiviral agents such as acyclovir, famciclovir, and valacyclovir [17–
20].
These antiviral agents are nucleoside analogues which are phosphorylated by viral thymidine
kinase and cellular kinases to a triphosphate form that inhibits viral DNA polymerase, leading
to a decrease of viral replication. Other types of antiviral agents such as foscarnet, vidarabine,
and cidofovir are not dependent on viral phosphorylation and noncompetitively block viral
DNA polymerase. In general, famciclovir and valaciclovir are accepted to have higher and
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more reliable levels of antiviral activity and bioavailability, although there is no systematic
data proving superior efficacy of one antiviral agent over another. In addition, valacyclovir
and famciclovir shows greater patient compliance than acyclovir with less frequent dosing
[21]. The main benefits of administration of antiviral agents within 72 hours are to reduce the
severity and duration of zoster-associated pain and the incidence of PHN [16]. Therefore, the
use of antiviral agents is crucial in treatment of HZ, and should be prescribed for patients with
HZ as soon as possible. In complicated cases, especially in ophthalmic zoster, disseminated
zoster, or Ramsay Hunt syndrome, and in patients failing oral treatment, intravenous therapy
should be considered. Many clinical trials suggest that antiviral agents should be started within
3 days of the cutaneous eruption [22–24]. In general, the recommended duration of systemic
antiviral agents for uncomplicated HZ is a seven-day course [17]. However, there is no solid
consensus about whether it is beneficial to extend the duration of the treatment for patients
with new onset vesicles after the seventh day, or for patients with either neurologic or ocular
complications [21]. In herpes zoster ophthalmicus, the ophthalmic division of the fifth cranial
nerve is involved, and the antiviral treatment should always be prescribed even after 3 days
of the disease onset [17]. In any case of ophthalmic herpes zoster, the patient should be seen
by an ophthalmologist as soon as possible, especially when vesicles on the side and tip of the
nose (Hutchinson’s sign) are present. In cases with the immunosuppressed patients, antiviral
therapy should always be started earlier because of the increased risk of herpes zoster
complications. The same doses as in immunocompetent patients are used in immunosup‐
pressed patients. The dosing regimen of the antiviral agents used in acute herpes zoster is
summarized in Table 1. Meanwhile, the efficacy of topical antiviral agents for acute HZ had
been shown to lack evidence [21].
Drug Regimen
Immunocompetent patient Immunocompromised patient
Famciclovir PO 500 mg every 8 hour for 7 days PO 500 mg every 8 hour for 7–10 days
Valaciclovir PO 1000 mg every 8 hour for 7 days PO 1000 mg every 8 hour for 7–10 days
Acyclovir PO 800 mg 5 times a day for 7 days PO 800 mg 5 times a day for 7–10 days or
IV 10 mg/kg every 8 hour for 7–10 days
PO, per oral, IV, intravenous.
Table 1. Summary of antiviral agents for treatment of acute herpes zoster.
2.2. Pain control
Since pain is the most troublesome symptom of herpes zoster, adequate pain management is
the mainstream of the treatment in conjunction with antiviral therapy. Most patients require
additional analgesics, although antiviral treatment may reduce the acute pain from HZ. In
addition, the effective relief of acute pain may reduce the risk of progression to PHN, because
severe acute pain is a risk factor for PHN. Acetaminophen, nonsteroidal anti-inflammatory
drugs (NSAIDs), and opioid analgesia may be used initially [25]. In patients experiencing
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insufficient pain relief with these agents, adjuvant analgesics such as antidepressants and
anticonvulsants are shown to be effective to alleviate acute pain from HZ [24]. If parts of the
pain of acute HZ may have inflammatory component, corticosteroids have been used during
the acute episode of HZ. In clinical trials with selected older individuals, corticosteroids
accelerate healing of the cutaneous lesion, improve quality-of-life measures, aid to return to
routine activities, and reduce analgesic use. Systemic steroids starting at about 1 mg/kg/day
for about 1 week, followed by 0.5 mg/kg/day for 1 week, and 0.25 mg/kg/day for another 1
week regimen is proven to be adequate to achieve these benefits [21]. If pain is refractory to
formerly discussed medications, nerve block or referral to a pain specialist for sympathetic
and epidural neural blockade can be performed.
3. Treatment of postherpetic neuralgia
PHN is difficult to treat and often resistant to the current pharmacologic therapies. A multi‐
modal analgesic treatment approach should be performed achieving both the efficacy and the
tolerability of the therapeutic regimen [26]. Currently, Food and Drug Administration (FDA)-
approved therapies for the treatment of PHN are the transdermal lidocaine and capsaicin
patches, gabapentin, and pregabalin. Therapies often use off-label or over-the-counter
medications for PHN include tricyclic antidepressants (TCAs), selective serotonin reuptake
inhibitors (SSRIs), opioids, antiepileptics, and nonsteroidal anti-inflammatory drugs
(NSAIDs). The dosing regimen and adverse effects of treatment options for PHN are sum‐
marized in Table 2.




Maximum of three 5% lidocaine
patches for 12 hours a day
Itching, burning sensation or erythema
on the application site
Topical
capsaicin
0.025% or 0.075% capsaicin cream
8% capsaicin patch
Anticonvulsants
Gabapentin Starting dose of 300 mg a day to




Pregabalin Starting dose of 100–150 mg a day
to maximum dose of 600 mg a day
Tricyclic antidepressant (TCAs)
Amitriptyline Starting dose of 10 mg at night
to maximum dose of 100 mg at night
Dry mouth, sedation, constipation,
increased appetite, blurred vision,
tinnitus, euphoria, urinaryNortriptyline Starting dose of 10–25 mg at night
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Treatment Regimen Adverse effects
with maintenance dose of
30–75 mg a day in
divided doses
retention
Desipramine Starting dose of 10–25 mg a day
to maximum dose of 150 mg a day
Opioid
analgesics
Tramadol Starting dose of 50 mg every 4–6 hour
(100–400 mg a day )
Morphine PO controlled release morphine:
Starting dose of 10 mg at
night to maximum dose of 200 mg a
day or divided dose of
10–30 mg every 12 hour
IV morphine: Target dose of
0.3 mg/kg over 1 hour
to maximum dose of 25 mg with
cardiopulmonary monitoring
Nausea, vomiting, constipation,
drowsiness, dizziness, mood change,
disorientation, somnolence, headache,
seizures
Oxycodone PO controlled release oxycodone:
Starting dose of 10 mg twice a day
to maximum dose of
60 mg a day
Methadone Starting dose of 5 mg
at night escalating dosage
till dose-limiting
side effects
PO, per oral, IV, intravenous.
Table 2. Summary of treatment options for pain management of post-herpetic neuralgia.
3.1. Pharmacological treatment
3.1.1. Topical agent
Topical application of anesthetics and analgesics may reduce pain with convenient delivery
of the pharmaceutical effect, improved patient adherence, and direct access to the target site
leading to decreased risk for systemic side effects. For localized and relatively mild pain,
topical agents may be a reasonable choice, especially in patients who cannot tolerate systemic
therapy. Currently available topical therapies include lidocaine and capsaicin patches. In
addition, in a small group of patients, topical application of a cannabinoid receptor agonist
resulted in pain reduction by more than 80% [27, 28].




Lidocaine relieves pain by reducing the ectopic activity of sensory nerves. The 5% lidocaine
patch has been shown in controlled clinical trials to produce significant pain relief in patients
with PHN and allodynia [29–32]. Often 7–10 days of treatment is required before efficacy is
noted. It is easy to use and systemic toxicity is not considered a significant risk in adults. Side
effects are usually limited to application site reaction, such as skin redness or rash, which may
necessitate the discontinuation of treatment. Therefore, topical lidocaine is a good first-line
treatment for elderly patients who have contraindications to systemic agents. The lidocaine
patch contains 5% lidocaine base, adhesive, and other ingredients. In general, maximum of
three patches are applied over the affected area for 12 hours a day. In addition, eutectic mixture
of local anesthetics (EMLA) cream applied once a day on the affected skin with an occlusive
dressing may perform as an adjuvant therapy [33].
3.1.1.2. Topical capsaicin
Capsaicin is an alkaloid derived from hot chili peppers and acts as a transient receptor potential
cation channel, subfamily V, member 1 agonist that activates afferent nociceptor terminals [34–
36]. Topical capsaicin has proven to effectively reduce pain than placebo in patients with both
musculoskeletal and neuropathic pain [37, 38]. Topical capsaicin demonstrates analgesia via
a counter-irritant mechanism in which the irritation of the affected area masks the pain
sensation of the skin. Also, repeated use of capsaicin results in depletion of substance P and
other neuropeptides from nociceptive fibers leading to desensitization of nociceptive terminals
[39]. Adverse effects are often limited to local reaction such as itching, burning sensation,
soreness, and erythema at the site of application, which may slowly disappear after continued
use. The systemic absorption is minimal. Application of low concentration (0.025 and 0.075%)
cream formulations for several weeks have shown efficacy in neuropathic pain. An 8%
capsaicin patch is also available for use in patients with PHN and HIV neuropathic pain [40,
41]. A Cochrane review in 2009 analyzed six studies treating with either a capsaicin 0.075%
cream or single application of 8% patch for chronic neuropathic pain. The authors concluded
that both concentrations of capsaicin may relieve pain, but there were insufficient data to prove
the degree of the benefit [42].
Although topical capsaicin monotherapy is generally not considered satisfactory for patients
with chronic pain, it can be helpful as an adjuvant therapy.
3.1.2. Systemic treatment
PHN is typically difficult to treat due to both unsatisfactory pain relieving effects of pharma‐
ceuticals and dose limitations related to intolerable side effects and drug-drug interactions.
Mainly, three classes of medication are used as standard therapies to manage PHN: anticon‐
vulsants, antidepressants (TCAs), and opioid analgesics.
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3.1.2.1. Anticonvulsants
Many anticonvulsants have been studied to treat chronic neuropathic pain disorders including
trigeminal neuralgia and PHN. Gabapentin and pregabalin have been documented as safe and
well tolerated anticonvulsant drugs helping to reduce zoster-associated pain. The mechanism
of the analgesic action of gabapentin and pregabalin has not been fully described. Both
gabapentin and pregabalin bind to the same receptor, α2δ subunits of voltage-gated calcium
channels in the central nervous system. Since gabapentin and pregabalin are both eliminated
from the systemic circulation primarily by renal excretion as unchanged drugs, the dosage of
these drugs should be adjusted based on the renal function of the patients.
3.1.2.1.1. Gabapentin
Gabapentin has been shown to be superior in relieving pain in 41–43% of patients with PHN
compared to 12–23% in patients receiving placebo [43, 44]. Gabapentin is absorbed slowly and
reaches a peak level at 3–4 hours after administration. Gabapentin is initiated at 300 mg daily,
escalating up to 3600 mg/day as needed for pain control. Pain relief occurs as early as one week
after the initiation of the treatment. Frequent adverse effects of gabapentin are somnolence,
dizziness, and peripheral edema. These adverse effects are usually short-lived, but they
sometimes require dose adjustment [29, 43].
3.1.2.1.2. Pregabalin
Pregabalin is a potent gabapentinoid and structural analog of γ-aminobutyric acid (GABA). It
is an ion channel modulator that has rapid analgesic, anticonvulsive, and anxiolytic effects.
Pregabalin has been shown to relieve pain by more than 50% in 50% of patients with PHN
compared to 20% in placebo groups [45, 46]. Dizziness, somnolence, and peripheral edema
were also the most often reported adverse effects for pregabalin, although pregabalin usually
has fewer dose-related adverse events than gabapentin because of the lower doses used [45–
47]. Pregabalin has improved pharmacokinetics with better absorption and steadier blood
levels and a faster onset of action than gabapentin. Therefore, titration of pregabalin to the
therapeutic dose range is more rapid [47]. Pregabalin can be given in two divided doses per
day, offering greater convenience than gabapentin [47, 48]. In general, the starting dose is 100–
150 mg/day in divided doses escalating to 300 mg/day within one week, considering tolera‐
bility and effectiveness. Further up regulation of the dose up to 600 mg/day in 2–4 weeks may
be considered for patients who experience unsatisfactory effect.
3.1.2.2. Tricyclic antidepressant
The TCAs work by blocking neuronal uptake of noradrenaline and serotonin, thereby
potentiating inhibition of spinal neurons involved in nociceptive perception. Since the TCAs
also block α-adrenergic receptors and sodium channels, they are known to be useful in PHN
in which damaged primary afferent neurons develop adrenergic sensitivity and generate
ectopic impulses closely related to sodium-channel blockade. In several randomized, control‐
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led trials, the TCAs have been shown to relieve pain in 44–67% of elderly patients with PHN
[26, 49–51].
The reported adverse effects of the TCAs include excessive sedation, cognitive impairment,
dry mouth, constipation, sexual dysfunction, and orthostatic dizziness. The contraindications
of the TCAs are patients with cardiovascular disease, glaucoma, and urinary retention. In
addition, the patients with high risk of suicide are administered with caution. In general, the
starting dose of TCAs is 10–25 mg/night for elderly patients. The dose may be increased by 25
mg nightly up to maximal dose. TCAs such as amitriptyline, nortriptyline, desipramine are
well studied and documented as effective managements of PHN.
3.1.2.2.1. Amitriptyline
Amitriptyline is a tricyclic antidepressant that is widely used to treat various chronic neuro‐
pathic pains including PHN. However, there is insufficient evidence to recommend amitrip‐
tyline as a first-line agent for neuropathic pain with an overestimation of treatment effect. A
Cochrane review in 2015 analyzed 17 studies involving 1342 oral amitriptyline-treated
participants. The authors concluded that amitriptyline should continue to be used as part of
the treatment of neuropathic pain, but only a minority of people will achieve satisfactory pain
relief [52]. Amitriptyline is started at a low dose of 10 mg/night, with gradual dose increase
up to 100 mg/night [11].
3.1.2.2.2. Nortriptyline
Nortriptyline, along with desipramine, is a preferred alternative treatment to amitriptyline
because of its lesser adverse effects for the elderly such as cardiac problems, sedation, cognitive
impairment, orthostatic hypotension, and constipation [53]. A recent Cochrane review in 2015
analyzed six studies treating 310 participants with various neuropathic pain conditions. The
authors concluded that little evidence supports the use of nortriptyline as effective treatment
for neuropathic pain [54]. The starting dose is 10–25 mg/night and the dosage may be increased
by 25 mg/day with 1 week interval. In general, maintenance dose is 30–75 mg daily in divided
doses, or a single night dose [11]. The most common side effects include dry mouth, sedation,
constipation, increased appetite, mild blurred vision, tinnitus, and often euphoria and mania
[55].
In a double-blind, randomized controlled trials, patients with diabetic polyneuropathy or PHN
were randomized to receive nortriptyline and gabapentin, alone or in combination [56].
Combination regimen of gabapentin and nortriptyline produced greater pain relief than either
agent alone. Therefore, combination therapy may benefit patients with PHN, but with higher
risk of adverse effects than with either drug alone.
3.1.2.2.3. Desipramine
A Cochrane review in 2014 analyzed five studies treating 177 participants with painful diabetic
neuropathy or PHN. The authors concluded that this review found little evidence to support
the use of desipramine as effective treatment for neuropathic pain, although there was very
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low quality evidence of benefit and harm [57]. In randomized, placebo-controlled, double-
blind, crossover studies, amitriptyline and desipramine have been shown to be effective for
the treatment of PHN [58, 59]. Results from these studies showed that 67% of patients taking
amitriptyline rated their pain relief as good to excellent, and 63% of patients taking desipra‐
mine rated their pain relief as moderate or better. Typically, the initial dose of desipramine for
treatment of PHN is 10–25 mg/day with a maximum dose of 150 mg/day [11].
3.1.2.3. Opioid analgesics
Pain management with opioids may also alleviate PHN. Although effective in treating PHN,
the issue of tolerance and concerns of misuse and abuse often tends to prevent opioids from
being used as first-line agents. Opioids regulate pain binding to the opioid receptors such as
μ, κ, δ and nociceptors present in both central and peripheral nervous system. The opioid
receptors are activated by binding to inhibitory G-proteins, resulting in closure of voltage-
gated calcium channels. This process leads to a cascade of potassium efflux causing hyperpo‐
larization and reduced cyclic adenosine monophosphate level, hence decreasing the neuronal
excitability. Additionally, opioids are capable of diverse and complex pharmacologic effects
because they may function with various potencies acting as an agonist, partial agonist, or an
antagonist binding to more than one receptor subtype. Side effects of opioids include consti‐
pation, cardiorespiratory dysfunction, sedation, nausea/vomiting, and histamine release [11].
Since constipation is a major side effect in elderly persons, bulk laxatives should be recom‐
mended. Additionally, the fact that many patients with PHN are elderly and have other
underlying diseases for which they are taking medication emphasizes the need for close
monitoring of adverse effects [11, 30, 60].
3.1.2.3.1. Tramadol
Tramadol is a synthetic 4-phenyl-piperidine analogue of codeine and acts as an analgesic with
both opioid and non-opioid analgesic activity. Besides the opioid analgesic activity, it works
via inhibition of noradrenaline reuptake and stimulation of serotonin release at the spinal level.
Thus, it has properties of both an opioid and a TCA. In a randomized clinical trial, tramadol
was proven to be an agent that significantly improve quality of life and alleviate pain in patients
with PHN [61]. Adverse effects of tramadol include nausea, vomiting, constipation, drowsi‐
ness, dizziness, somnolence, headache, and seizures. Concomitant use of SSRIs, selective
serotonin-and norepinephrine-reuptake inhibitor (SSNRIs), or TCAs should be avoided and
drug interactions should be monitored [24]. It is generally dosed at 100–400 mg/day, in divided
doses. The starting dose is 50 mg every 4–6 hours [26, 49].
3.1.2.3.2. Morphine
In a crossover trial with patients suffering PHN, both controlled release morphine and TCAs
provided significant pain relief compared to placebo group [62]. In this report, patients
preferred treatment with opioid analgesics to either TCAs or placebo, despite a higher
incidence of adverse effects and more dropout patients during opioid treatment. In another
crossover trial, patients with diabetic polyneuropathy or PHN were randomized to daily active
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placebo, sustained-release morphine, gabapentin, and a combination of gabapentin and
morphine [63]. Combination regimen with morphine and gabapentin showed superior effect
in pain relief than either agent alone or the active placebo, but with increased adverse effects.
The starting dose of oral controlled release morphine is 10 mg/night and the dose is increased
twice weekly till maximal dose of 200 mg/day. Also, it can be given at divided dose of 10–30
mg every 12 hours as needed [62]. For intravenous morphine, the target dose is 0.3 mg/kg over
1 hour, up to a maximum of 25 mg with cardiorespiratory monitoring in inpatient setting [64].
The adverse effects include nausea, vomiting, constipation, drowsiness, dizziness, mood
change, and disorientation [26, 49].
3.1.2.3.3. Oxycodone
A Cochrane review in 2014 analyzed three studies treating 254 participants with painful
diabetic neuropathy or PHN. In all three studies, controlled release oxycodone was used with
doses titrated up to a maximum of 60–120 mg daily. The authors concluded that no convincing,
unbiased evidence suggesting oxycodone is of value in treating patients with painful diabetic
neuropathy or PHN exists [65]. However, other randomized, placebo-controlled crossover
trials suggest greater efficacy of controlled release oxycodone over placebo [66]. The dose is
10 mg twice daily, up to a maximum of 60 mg/day. Adverse effects are typical of other opioids
[30].
3.1.2.3.4. Methadone
Methadone is a synthetic opioid agonist that exhibits a potent antagonist effect on glutamate
N-methyl-D-aspartate (NMDA) receptors. Although there is a great paucity of clinical
evidence regarding the treatment effect of methadone on PHN, methadone may be tried as an
adjunctive treatment for PHN. In a recent double blind and placebo controlled study, metha‐
done, when compared to placebo, did not significantly affect the intensity of spontaneous pain,
as measured by the visual analogue scale [67]. However, the intensity of spontaneous pain was
significantly decreased after the methadone treatment, compared to placebo by the category
verbal scale (50% improved after the methadone treatment, none after the placebo, p=0.031).
Evoked pain was reduced under methadone compared to placebo (50% improved after the
methadone treatment, none after the placebo, p=0.031). The starting dose is 5 mg/night and is
increased till maximal pain relief is achieved or occurrence of dose-limiting side effects.
Methadone has a high intestinal absorption, and most of the drug is excreted in feces with no
significant renal elimination, hence this drug is safe for patients with renal failure [68].
3.2. Non-pharmacological treatment
As a general rule, non-pharmacological, interventional pain management is frequently used
in acute settings or in patients who have failed the standard therapies.
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3.2.1. Nerve block
The interventional treatments including sublesional anesthesia, epidural blocks, intrathecal
injection, and sympathetic nerve blocks with and without corticosteroids have been reported
in large series, but rarely studied in a controlled manner. They have limited evidence of
effective treatment of PHN [29]. Epidural block with local anesthetics and steroids is not
effective in providing long-term pain relief in patients with PHN. Sympathetic nerve blocks
have shown beneficial effects in patients with acute HZ, but with insufficient effect in provid‐
ing long-term pain alleviation in patients with PHN [69]. Long-term pain relief by peripheral
nerve block using local anesthetics has been reported, but with limited quality of the evidence
[70].
3.2.2. Spinal cord stimulation
Spinal cord stimulation (SCS) has been used for the management of chronic neuropathic pain
disorders [71, 72]. However, no randomized controlled study supports the usefulness of SCS.
Studies on SCS were all case series with a small number of cases [73–75]. Therefore, SCS should
be used only as a next resort after intrathecal steroid injections or nerve blocks in patient’s
refractory to pharmacological treatments of PHN.
3.2.3. Transcutaneous electrical nerve stimulation
Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by
a device to stimulate the nerves at a strong but nonpainful intensity that can produce pain
relief [76]. TENS is an adjunctive therapy that has shown efficacy in transiently relieving
neuropathic pain [77, 78]. In a study of TENS for patients with chronic pain, approximately
30% of patients with PHN fail to respond to TENS and among patients who respond initially,
only a third continue to obtain pain relief after 2 years [77]. In a recent pilot randomized study
of patients who were refractory to previous pharmacological therapy, the patients were treated
with TENS with a biofeedback capability [79]. After every two treatments with the sham and
true device, the patients were required to fill out a standard neuropathic pain scale score. The
patients had choices to select the other device after three consecutive treatments if they felt an
insufficient relief in their pain. The true device was chosen over the sham device by all patients.
The majority of these patients treated by the true device reported a significant decrease in pain
scores.
3.2.4. Botulinum toxin
BTX-A may play an adjunctive role as a promising therapeutic modality for PHN with its
proven efficacy, safety, and tolerability. Botulinum toxin A (BTX-A) blocks acetylcholine by
cleaving synaptosomal-associated protein of 25 kDa (SNAP25), which participates in the
formation of the exocytic soluble N-ethylmaleimide–sensitive factor attachment protein
receptor complex(SNARE) that is essential for the fusion of acetylocholine-containing vesicles
with the presynaptic membrane [80, 81]. Therefore, the local peripheral BTX-A injection may
result in anti-nociceptive effect associated with the inhibition of formalin-induced glutamate
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release, substance P and calcitonin gene–related peptide, which participates in the neurogenic
inflammation [82]. There are several case series and randomized controlled trials supporting
both therapeutic benefit and safety of BTX-A on PHN patients [83–88]. In these studies, no
significant safety issues including local or systemic adverse effects was raised except the pain
during injections. A possible consideration to BTX-A use is that, unlike other therapeutic
modalities for PHN, it may induce antitoxin antibodies that could probably limit the long-term
repetitive use of the treatment [89].
4. Vaccination against herpes zoster
In a randomized trial with elderly patients, adult vaccination reduced the incidence of herpes
zoster by 51% and the incidence of postherpetic neuralgia by 66%. In patients 70 years of age
or older as compared with patients 60 to 69 years of age, the vaccine was less effective in
reducing the risk of herpes zoster (38% reduction) but demonstrated similar protection against
PHN (67% reduction) [90]. A live attenuated VZV vaccine has been available since 2006. It is
a one-dose, high-potency vaccine originally approved for immunocompetent persons 60 years
of age or older, but in 2011, it was approved to include persons aged 50–59 years [91]. This live
attenuated vaccine is contraindicated in pregnant women and immunocompromised individ‐
uals. The reported side effects of the vaccine are minor, such as erythema, pain, and an itching
sensation at the injection site, and fever [90]. Regarding the persistence of vaccine efficacy, the
Shingles Prevention Study demonstrated the proven efficacy of the vaccine through four years
post-vaccination. Additionally, the Short-Term Persistence Substudy subsequently demon‐
strated the persistence of vaccine efficacy through five years post-vaccination, although the
efficacy beyond five years is uncertain [92]. Overall, the zoster vaccination can be used as the
first line management for the prevention of HZ and PHN.
5. Conclusion
As the general population ages, the number of patients suffering from HZ and PHN may
increase gradually in the future. Diverse and comprehensive efforts are necessary as patients
suffering from acute HZ and PHN are burdened by a worse quality of life due to both physical
and psychological impairments [11]. We summarized the management of acute HZ and PHN
to shorten the duration and intensity of pain. In order to choose the optimal treatment,
clinicians should consider issues related to efficacy, safety, and tolerability in conjunction with
individuals’ goals of therapy, preferences, and adherence issues. Finally, regardless of the
agents chosen, the adverse effects and drug interactions should always be considered to
provide safe and effective management of pain.
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Abstract
Osteoarthritis (OA) of the knee is the commonest degenerative joint disease affecting older
adults. Risk factors for the knee OA includes female gender, advanced age, overweight,
obesity, previous knee injuries, previous knee surgery, and certain jobs that require
continuous knee bending. Pain is the major symptom of knee OA and increased pain
causes reduced physical function and poor quality of life. In addition to pain, patients
may have joint stiffness, knee extensor muscle weakness, and altered proprioception. A
multitude of structural, physical, and psychosocial factors influences symptom and
severity of pain in knee OA. Rehabilitation of knee OA aims to train the patients in coping
strategies, improves physical health, quality of life, and maintains their independence in
daily livings. Management of knee OA often requires a combination of pharmacologic
and nonpharmacologic treatment approaches.
Keywords: Knee, osteoarthritis, pain, rehabilitation, physiotherapy
1. Introduction
Osteoarthritis (OA) of the knee is a prevalent musculoskeletal disorder causing pain and
disability  in  older  population  [1].  Worldwide  statistics  indicates  more  than  100  million
individuals globally affected by OA [2, 3]. The prevalence of OA is expected to double at the
end of the year 2020 [4]. The prevalence of symptomatic knee OA in male and female is
approximately 40 and 47%, respectively [5]. Evidence of radiographic knee OA in the United
States is approximately 19% in adults aged 45 years and older [5]. While male and female are
equally affected by OA, it is reported to be more common in young adult male (<45 years) and
in the older adult female (>45 years) [6–9].
Risk factors for the knee OA includes female gender, advanced age, overweight, obesity,
previous knee injuries, previous knee surgery, and certain jobs that require continuous knee
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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bending (kneeling and lifting) [10, 11]. Biomechanical factors including, abnormal joint
congruity, muscle weakness, mal-alignment, or internal derangement of knee, facilitate the
progression of knee OA in those persons, who are susceptible to the development of the knee
OA [12, 13]. Lower extremity muscle weakness has vital role in the progression of the knee
OA [14, 15]. Previous studies indicate that weaker quadriceps muscle is associated with
symptomatic knee OA and weakness of muscles increases the risk of physical disability [14, 15].
Knee OA can be classified either symptomatically or radiographically. The Kellgren–Lawrence
(KL) [16] grading scale has been used to diagnose radiographic knee OA. The symptomatic
knee OA has been diagnosed clinically followed by radiographic confirmation.
The symptoms of knee OA includes pain, stiffness, limited range of motion, swelling, crepitus,
and muscle weakness [17, 18]. Knee pain significantly influences physical function depending
on the site of pain and unilateral or bilateral involvement [19]. Knee pain affects variety of
activities including the limited ability to use stairs, standing up from the chair, walking on
uneven terrain, floor sitting, and squatting [20–22].
Rehabilitation of knee OA aims to train the patients in coping strategies, improves physical
health, quality of life, and maintains their independence in daily livings. These goals can be
achieved by variety of interventions including, pharmacological approach, physical therapy,
education, weight reduction, orthotic, and surgery.
2. Risk factors
There are variety of risk factors including age, gender, occupation, osteoporosis, genetics,
nutritional factors, previous injury, knee extensor muscle weakness, and obesity [23, 24]. A
recent meta-analysis provides further evidence that increased body mass index (BMI), past
knee injury, age, female gender, and hand OA are the major risk factors causing knee OA [11].
The frequency of OA is increased in older population. In the United Kingdom, up to 40% people
above the age of 65 years has been suffering from the symptoms associated with knee or hip
OA [25]. While male and female are equally affected by OA, it is reported to be more common
in the young adult male (<45 years) and in the older adult female (>45 years) [6–9].
A previous study reported some occupational activities, for example, kneeling, high levels of
physical activity, farming, and construction work are potential risk factors for developing knee
OA [11]. Another study reported double the risk of developing knee OA in individuals whose
jobs required carrying and kneeling, or squatting activities compared to individuals whose
jobs did not require such physical activities [26]. In addition, jobs which require repetitive task
or sports, particularly endurance sports in which joint injuries are common, may predispose
OA [27].
Obesity is recognized as major risk factors for mechanical joint damage, particularly in weight-
bearing joints, and is often present with sedentary people with knee OA [28, 29]. The risk of
incidence and progression of lower extremity OA increases with obesity [30], and the risk of
knee OA increases four times more compared with individuals with a BMI of <30 kg/m2 [31].
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Another study reported 83% of the female participants had knee OA who were obese compared
to 42% of non-obese control group [32]. In addition, obesity can alter the mechanics of joint
and develop inflammation and cause increased pain [33, 34]. Furthermore, increased fat
around the quadriceps muscle causes reduced activity of the muscle, resulting in decreased
function [35].
Previous studies had reported knee extensor muscle weakness, a major risk factor for knee
OA, especially in women [36, 37]. Other studies found knee extensor muscle weakness in
people with knee OA compared to control subjects [7, 15, 38]. In addition, Segal et al. [39]
reported low risk of symptomatic knee OA in individuals with greater quadriceps muscle
strength. The weakness of quadriceps muscle causes reduced functional disability in knee OA
[22]. Furthermore, the presence of pain causes disused atrophy which results quadriceps
weakness in knee OA [14].
3. Diagnosis of osteoarthritis
The diagnosis of the OA often made clinically, and radiological features confirm the diagnosis.
The presence of pain in the knee, morning stiffness lasting over the 30 min, limited movement,
crepitus, swelling, and advanced age usually the main characteristics that indicate the
diagnosis of knee OA. The narrowing of joint space, sclerosis of subchondral bone, and
formation of subchondral cyst and osteophytes are radiological features seen in knee OA [40].
Kellgren and Lawrence [16] have developed a radiological scale to classify knee OA into four
grades on antero-posterior view of radiograph taken in standing position. “Grade 0 is defined
as no radiographic findings of osteoarthritis, Grade 1 as minute osteophytes of doubtful clinical
significance, Grade 2 as definite osteophytes with unimpaired joint space, Grade 3 as definite
osteophytes with moderate joint space narrowing, and Grade 4 as definite osteophytes with
severe joint space narrowing and subchondral sclerosis” [41]. In addition, the American
Rheumatism Association (ARA) has developed a more specific classification system in 1986,
known as the American College of Rheumatology (ACR) criteria. These criteria included
several validated clinical and radiological features [42].
4. Clinical manifestations
Pain is the major symptom of knee OA, and increased pain causes reduced physical function
and poor quality of life [43]. In addition, knee pain causes difficulty in performing activities
of daily livings including shopping, household chores, stair climbing as well as participation
in social and outdoor activities [44]. Furthermore, pain related to knee OA influences work
productivity and employment status [45]. In addition to pain, patients may have joint stiffness,
knee extensor muscle weakness, and altered proprioception [46–48]. These symptoms often
cause restriction in the ability to get up from the chair, difficulty in walking, and stair climbing
[46]. Limping gait, poor limb alignment, and instability are some other features seen in people
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with knee OA [49]. A crepitus sound can be heard during movements due to the presence of
irregular joint surfaces in knee OA [50].
A multitude of structural, physical, and psychosocial factors influences symptom and severity
of pain in knee OA [43, 51, 52]. Although the role of nociceptors in the capsule, subchondral
bone, ligaments, and other joint tissues precipitation symptom of pain was established,
however, structural deformation in knee OA is not associated with the severity of pain [53].
Previous studies reported that the impairments in the physical and psychological functions
are the major predictors of the severity of knee pain. Reduced muscle strength, especially of
the quadriceps, is associated with severity of pain and low level of physical function [52, 54].
Psychological impairments such as pain catastrophizing [55], reduced pain coping skills [56],
depression [57, 58], anxiety [57], and reduced social participation [58] are also associated with
the severity of pain in individuals with knee OA. Furthermore, pain and physical and
psychological impairments have shown bi-directional relationships, that is, physical and
psychological impairments can influence, and in turn be influenced by severity of pain, results
a further reduced physical and mental functioning [59].
5. Rehabilitation
Management of knee OA often requires a combination of pharmacologic and nonpharmaco‐
logic treatment approaches [60, 61]. Several clinical guidelines have been published by the
scientific society for nonpharmacological treatment approach in knee OA [62–68]. Several
randomized, controlled clinical trials have been published showing therapeutic effectiveness
of exercise-based approaches, including range-of-motion exercises, aerobic exercise programs,
and muscle-strengthening exercises [60, 61, 69, 70]. A previous study reported significant
reduction in pain and functional disability scores of the Western Ontario and McMaster
Universities (WOMAC) outcome measure following a home exercise program [69]. Another
study reported significant reduction in pain following isometric quadriceps exercises for 3
months in knee OA [70]. Stitik et al. [71] had reported a significant reduction in pain intensity
following combined use of hyaluronate injections and home exercise program in moderately
severe pain in individuals with knee OA. Furthermore, previous randomized controlled
studies reported that a simple quadriceps exercise performed at home was effective in reducing
pain as well as functional disability [72, 73]. Another study reported a significant reduction in
pain intensity and improved function following a simple group education program in patients
with knee OA [74].
Passive treatment in the form of physiotherapeutic modalities such as short-wave diathermy,
transcutaneous electrical nerve stimulation (TENS), ultrasound and hot packs often used to
reduce both acute and chronic pain in knee OA [75]. However, Moffett et al. [76] reported that
the short-wave diathermy had no additional benefits than placebo effects when used for 3
weeks in knee OA. In a recent published review, Zeng et al. [77] reported that the interferential
current seems to be effective pain relief intervention in knee OA. Furthermore, they recom‐
mended that the other electrical stimulation therapy such as TENS, neuromuscular electrical
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stimulation, pulsed electrical stimulation, and noninvasive interactive neurostimulation is
either uncertain or not appropriate for pain relief in knee OA [77].
Fransen and McConnell published a Cochrane review, in which, land-based therapeutic
exercise (aerobic, resistance, stretching, strengthening, and range-of-motion exercises exercis‐
es) was compared with the non-exercise control group (home visits, education, waiting list,
telephone call, relaxation, no intervention) in patients with hip or knee OA. The results of
review indicate a significant reduction of self-reported pain and physical function for thera‐
peutic exercise compared with control group [78]. Quadriceps strengthening is vital for
alleviating pain and improving function in individuals with medial compartment knee OA
[79]. Previous studies reported a reduced pain and improved function following knee flexors
and extensors or hip abductors strengthening in knee OA [80–83]. Recently, a systematic
review of 18 randomized controlled trials published, most of the included studies involved
home-based exercise of quadriceps or lower extremity strengthening in knee OA. The results
of this study indicate a significant reduction of pain and improvements in self-reported
physical function following strengthening exercise in knee OA [79]. In another review, aerobic
walking or home-based quadriceps-strengthening exercise was compared with a non-exercise
control group in patients with knee OA. The results of review indicate both the types of exercise
(aerobic walking or home-based quadriceps-strengthening exercise) significantly reduced
knee pain compared with control group [84].
Cognitive behavioral therapy (CBT) is a psychological approach to train and enhance pain
coping skills and found to be effective in reducing pain and improvement in self-efficacy in
patients with knee OA [85–88]. CBT protocol includes three components: (i) patients education
about the pain and the effect of pain coping skills on pain reduction, (ii) use of several cognitive
and behavioral pain coping skills in a systematic manner, and (iii) the most challenging is to
teach the patients how to use learned coping skills in a real-life situations [89]. A meta-analysis
published recently had found that CBT is the most common studied psychosocial therapy
approach for pain management in patients with arthritis [85]. Other studies recommended the
use of pain coping skills training based on CBT, to reduce pain and improve psychological
well-being in chronic pain conditions in patients with knee OA [90, 91].
Various other treatment techniques had shown significant effects on pain reduction in knee
OA. Hinman et al. [92] reported significant reduction of pain following 3 weeks of therapeutic
taping. Mulligan’s mobilization with movement (MWM) technique seems to provide
immediate pain relief and improved function in patients with knee OA [93]. Previous study
recommended the use of laterally elevated wedge insoles inserting inside the shoes in patients
with medial compartment knee OA [94]. Another study reported significant relief of pain using
laterally elevated wedged insoles compared to neutrally wedged insoles in patients with knee
OA [95]. However, other study reported no additional benefits of using braces and orthoses
for the management of knee OA [96].
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Abstract
The application of radiofrequency is a treatment for many clinical conditions such as
trigeminal neuralgia, complex regional pain syndrome, chronic postsurgical pain, cancer
pain, hyperhidrosis and facet joint pain requiring ablation of different nerve locations. In
this procedure, a constant high-frequency, high-temperature electrical current is applied
to target tissue. Sluijter has achieved significant pain relief using radiofrequency current
at a temperature below 42°C that produced strong electromagnetic field with no thermal
lesion and referred as pulsed radiofrequency. The use of pulsed radiofrequency is a non-
neurodestructive and therefore less painful technique, and it serves as an alternative
method to continuous radiofrequency.  Many studies  have demonstrated favorable
outcomes with pulsed radiofrequency compared to continuous radiofrequency.
This chapter suggests the use of continuous and pulsed radiofrequency with a minimal‐
ly invasive procedure for patients with chronic pain as an alternative to surgical treatment
and it might be an additional option among nonsurgical treatment methods.
Keywords: pain, treatment, pulsed radiofrequency, minimally invasive surgical pro‐
cedures, continuous
1. Introduction
The application of radiofrequency (RF) electrical signals to neural tissue with an RF lesion
generator and RF electrodes inserted into the tissue is common to treat pain [1] and other
diseases such as atrial fibrillation [2], malignant liver tumors [3], intermediate and large bone
tumors [4] and varicose veins [5]. The basis of this method is to generate enough RF heating
power in the tissue to raise the temperature above 45–50°C which is referred as the “lethal
temperature”, as the tissue exposed to these temperatures for 20 s or more are known to be
destroyed by the heat [1].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
The earliest RF lesion generators and electrodes were built by Cosman et al. in the early 1950s.
They used continuous-wave RF with 0.1–1 mHz frequency and therefore referred as continu‐
ous RF lesioning [6, 7]. The basic principles and properties such as shape and size of heat lesions
caused by for different electrode geometries and temperatures are well described today [8].
Recently, another RF method is especially used for pain treatment in which short pulses of RF
signals are applied to the neural tissue through the RF electrode. This method is referred as
pulsed RF lesioning [9].
While continuous RF used power sources with 0.1–1 mHz frequency range to produce RF heat
lesion, pulsed RF signals have pulse durations ranging from 10 to 30 ms, and pulse repetition
rates ranging from 1 to 8 Hz (pulses per second) [1]. Pulsed RF which produces a lesion to
nerve tissue by transmission of high-voltage current through thermocouple probe has been
used as a non- or minimally neurodestructive technique alternative to heat lesions because the
average tissue temperature rise is less than continuous RF with the same voltage [1, 10–14].
Sluijter has achieved significant pain relief using radiofrequency current at a temperature
below 42°C that produced strong electromagnetic field with no thermal lesion [9–11].
The objective of this book chapter is to explain the physics, operating principles, the mechanism
of action, contraindications, complications and evaluation of efficacy of pulsed RF and
continuous RF therapies in chronic pain management, in addition discussion of examples of
clinical procedures.
2. The physics and operating principles of radiofrequency
RF lesioning is based on the principle of a very-high-frequency current passage down a 27G
thermocouple probe which is inserted through a special 22G fully insulated cannula except
for its tip. The current passes down the thermocouple probe and heats the surrounding tissues
to a temperature controlled by the operator. The location of the nerve is achieved by a
stimulating current with the thermocouple probe, and with a destructive current a circum‐
scribed lesion is created. The lesion is shaped like a match with a diameter of about 2–4 mm
[1, 11, 12].
The cannula, placed close to the targeted nerve to be lesioned, is usually confirmed under X-
ray. Then, stylet of cannula is removed and replaced by the thermocouple probe. The operator
initially attempts to seek the nerve by low-voltage stimulation at a frequency of 50 Hz, aiming
the strongest sensory stimulation at the lowest possible voltage. The cannula needs to be within
3 mm of the nerve in order to create an adequate lesion and a maximum stimulation level of
around 0.6 V would indicate this. The operator should always ensure that the cannula is not
dangerously close to any motor nerve when trying to lesion a sensory nerve [1, 10–12].
When the operator is satisfied that the needle is in a safe place, a radiofrequency current (about
300–500 kHz) is passed through the thermocouple probe. The current heats up the surrounding
tissues and produces a lesion in the targeted nerve. At a temperature of below 44–50°C, no
permanent neurological damage will occur; thus, for practical purposes, when we mention
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lesion size, we mean the volume of tissue within the 44–50°C. In all cell types, the heating of
tissue above 44–50°C for several minutes will indeed result in cell death [1, 10–12].
In order to eliminate any possibility of a heat lesion being produced, Sluijter suggested a
radiofrequency technique which uses a temperature of no greater than 42°C and which utilises
the strong electric field generated by the passage of the radiofrequency current to achieve pain
relief [12]. In order to apply an electric field to the tissues, without raising the tip temperature
above 42°C, the radiofrequency current can be applied in a pulsed fashion. The “silent” period
between pulses allows for the dissipation of heat produced during the active cycle [12].
Cosman and Sluijter have modified the standard lesion generator to deliver radiofrequency
current bursts of 45 V at a repetition rate of 2 Hz with each burst 20 ms long; the rest period is
therefore 480 msec. This is defined as pulsed RF [10–12, 15, 16].
The resistance to the current flow can be measured and it is useful in certain procedures since
it indicates the position of the needle tip. The impedans will be 400 Ω in extradural tissues and
measuring a 200 will warn operator that the tip is passed to the cerebrospinal fluid (CSF) and
a 800 Ω impedans will indicate when the tip enters CSF during percutaneuous cordotomy.
Similarly, during procedures with intervertebral disc, an impedans is very high and it falls
below 200 Ω while nucleus pulposus impedans of nucleus pulposus is reached [1, 10–12].
3. Mechanism of action of radiofrequency
Continuous RF lesioning involves the passage of a very high frequency which causes destruc‐
tion by heat. It is simple and clear. Efficacy of pulsed RF has been clinically documented and
has been used for chronic pain conditions for the last 20 years, but its mechanism of action is
not fully understood [10–14]. It has been suggested to alter gene expression in neurons, by
means of neuromodulation [1, 11, 17–23]. Stimulation of serotonergic and noradrenergic
systems and induction of descending pathways have also been proposed [22]. There is no
clinical evidence of any nerve damage with pulsed RF [11, 12, 19, 22, 23]. Higuchi et al. have
presented experimental evidence that pulsed RF applied to the rat cervical dorsal root ganglion
causes upregulation of the immediate early gene c-fos immunoreactivity in the laminae I & II
of the dorsal horn [18]. Hamann et al. applied pulsed RF to the sciatic nerve or the L5 dorsal
root ganglion in the rat. They studied the expression of activating transmission factor 3 (ATF3),
an early intermediate gene expressed in response to cell stress. They also reported a trend
downregulation of CGRP expression [24]. Hamann et al., pointing out the lack of laboratory
evidence for this phenomenon, felt that this may be due to changes induced in the function of
the Schwann cells [24]. Electric fields have demonstrated effects on immune modulation, as
there are studies that show proinflammatory cytokines, such as interleukin (IL)-1b, TNF-alpha
and IL-6, are attenuated by electric fields [25]. Upregulation of adenosine A2A receptor density
has also been observed in human neutrophils treated with generated electric fields, and this
appeared to be associated with inhibition of the catabolic cytokines, such as TNF-alpha, IL-6
and IL-8 [26].
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In an animal study evaluating the histologic effects of continuous RF at 67°C and pulsed RF
applied adjacent to rabbit dorsal root ganglia (DRG), Erdine et al. found mitochondrial
degeneration and a loss of nuclear membrane integrity in the continuous, but not in the pulsed
group [27]. Another histopathologic study, comparing the effects of continuous RF and pulsed
RF delivered at 42°C on the rat DRG and sciatic nerve, showed no structural changes aside
from transient endoneurial edema and collagen deposition [28]. In addition, Hagiwara et al.
more recently demonstrated that pulsed RF may actually enhance the descending noradre‐
nergic and serotonergic inhibitory pathways, which are intimately involved in the modulation
of neuropathic pain [22]. Pulsed RF may be useful and continuous RF is contraindicated, e.g.,
in neuropathic pain and it is safe in locations where continuous RF may be potentially
hazardous, e.g., DRG lesioning. It is virtually painless as no heat is generated [10–12].
Sluijter describes four phases in a pulsed RF treatment procedure:
a. A stunning phase, which provides immediate relief.
b. A phase of post procedure discomfort, which may last for up to 3 weeks.
c. A phase of beneficial clinical effect, which has a variable duration.
d. A phase of recurrence of pain, we are still in the early days but many cases record 4–24 months of
relief [11, 12].
4. Contraindications of radiofrequency
Gauci does not recommend the use of both continuous and pulsed RF in patients with
psychological overlay, drug dependency and total body pain [12]. Continuous RF treatment
is also contraindicated in all nerve that carries motor fibers [1, 10–13].
Pulsed RF therapy seems ineffective in some diseases and would be contraindicated. Whereas
according to some studies, pulsed RF appears to be ineffective in our opinion; one of the
reasons for this is the insufficient “pulsed RF dose” applied. For example, in a study the anti-
allodynic effects of pulsed RF was significantly greater when pulsed RF exposure was
increased from 2 to 6 min [29]. Therefore, there also exist unresolved questions regarding the
effective “pulsed RF dose” based on voltage settings and duration of pulsed RF treatment,
which require further clinical studies in order to confirm.
5. Complications of radiofrequency
The high temperature applied with continuous RF is neurodestructive and is usually
characterized by a period of discomfort, including hypoanesthesia and a neuritis-like reaction
[1, 10–14]. Sometimes pain may potentially worsen due to nerve regeneration and may lead
to neuroma formation. Other complications such as hematoma, numbness, transitory diplopia,
meningitis, Horner’s syndrome and urinary retention may occur [12–14, 16, 17, 19, 30, 31].
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In the publication of Cahana et al., it is stated that there is documentation of more than 1200
patients who have been treated with pulsed RF and no neurological complication was reported
[23]. In a recent clinical study on patients with premature ejaculation, pulsed RF was performed
to dorsal nerves of penis and no functional disorder that indicates a nerve lesion was deter‐
mined [19]. We have not observed such a complication in our clinical experience.
6. Procedure for application of radiofrequency
The applications of continuous and pulsed RF in our department were made in operating
room. Before procedure, prothrombin time and platelet counts were checked. Following a
peripheral IV route, the patients were monitorized with ECG, oxygen saturation and non-
invasive arterial blood pressure and sedated with 0.02 mg/kg IV midazolam. Following
subcutaneous local anesthetic infiltration, a RF lesion generator was used for continuous and
pulsed RF thermal ablation. A 22-gauge, 5–15 cm, RF cannula with a 2–10 mm active-pinned
tip (with matching electrode) is advanced to the target tissue. The electrode of the RF device
is placed on the cannula, and the impedance is seen to be between 200–400 Ω. In order to check
the position of the cannula neurophysiologically, paresthesia is observed with 50 Hz sensory
stimulation at 0.3–0.5 V and lack of motor contraction with 2 Hz motor stimulation at 0.9–1.5
V. After this neurophysiological testing, continuous RF thermal coagulation is applied at 60–
80°C for 60–120 s. Pulsed RF thermal coagulation is applied at 42°C for 120–600 s. Following
thermal coagulation, 2 ml of 2% lidocaine is applied through the cannula. All patients are
monitored for potential complications following 2 h after the procedure. Patients were
discharged home on the same day.
7. Applications of radiofrequency treatment
a. Radiofrequency facet joint denervation
• Cervical facet joint denervation [12, 32–35]
Target: Medial branch of the cervical posterior primary ramus
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5 cm length, 2–4 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Supine and the X-ray tube “looks” at the side opposite to that being
treated (C2–C5), prone (C6–C7)
View: Lateral-oblique view of the cervical spine (C2–C5), postero-anterior-oblique view
of the cervical spine (C6–C7)
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Treatment modality: Continuous RF (80°C for 60 s), pulsed RF (42°C for 120–360 s)
• Thoracic facet joint denervation [12, 32, 34, 35]
Target: Medial branch of the thoracic posterior primary ramus
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5–10 cm length, 2–4 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior view of the thoracic spine
Treatment modality: Continuous RF (80–85°C for 60 s), pulsed RF (42°C for 120–360 s)
• Lumbar facet joint denervation [12, 32, 34–36]
Target: Medial branch of the lumbar posterior primary ramus (eye of the Scottie dog,
L1–L4), the junction between the superior articular process and the upper surface of
the lateral part of the sacrum (L5), just lateral to the sacral foramen (S1–S3)
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 10–15 cm length, 5 mm active-pinned tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior-oblique view of the lumbar spine (tunnel vision)
Treatment modality: Continuous RF (85°C for 60 s), pulsed RF (42°C for 180–360 s)
b. Radiofrequency dorsal root ganglion
• Cervical DRG pulsed RF/continuous RF [12, 34, 35, 37]
Target: Typical cervical DRG (C3–C6)
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5–10 cm length, 2 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Supine and the X-ray tube “looks” at the side opposite to that being
treated (C1–C6), prone (C7–C8)
View: Lateral-oblique view of the cervical spine (C2–C5), postero-anterior-oblique view
of the cervical spine (C6–C7)
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (65°C for 60 s) (do not
carry out C1–C2)
Attention: The vertebral artery may lie in needle path. Careful! (C1–C2)
Pain Management100
• Thoracic DRG pulsed RF/continuous RF [12, 34, 38–40]
Information: Effective in the treatment of chronic thoracic postherpetic neuralgia and
chronic postsurgical thoracic pain
Target: Thoracic DRG
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 10 cm length, 2 mm active-curved tip (with matching electrode)
of the RF, the grounding line
Patient position: Prone
View: Postero-anterior-oblique view of the thoracic spine, angle your beam slightly
cranially (T1–6), angle your beam slightly caudally (T7–12)
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (67°C for 60 s)
Attention: Pneumothorax! Careful!
• Lumbar DRG pulsed RF/continuous RF [12, 27, 41–43]
Information: Effective in the treatment of chronic post-amputation stump pain and
complex regional pain syndrome
Target: Lumbar DRG
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 10–15 cm length, 2 mm active-pinned tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior-oblique view of the lumbar spine (no double end plate) (chin of
the dog)
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (50–65°C for 60 s)
c. Radiofrequency sympathetic nervous system
• Sphenopalatine ganglion pulsed RF/continuous RF [12, 44–47]
Information: Effective in the treatment of posttraumatic headache, chronic face and
head pain and cluster headaches
Target: Pterygopalatine fossa, pterygomaxillary fissure
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5 cm length, 2 mm active-pinned tip (with matching electrode)
of the RF, the grounding line
Patient position: Supine and the X-ray tube “looks” at opposite to the treated side
View: Lateral-oblique X-ray view of skull to show pterygomaxillary fissure
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Treatment modality: Pulsed RF (42°C for 120–240 s), continuous RF (60–90°C for 60–90
s)
• Superior cervical ganglion pulsed RF/continuous RF [12, 48]
Information: Effective in the treatment of tinnitus and atypical face pain
Target: The superior cervical sympathetic ganglion is formed by the coalescence of the
upper four cervical sympathetic ganglia. It is situated at the level of C3, postero-medial
to the carotid sheath and to the internal jugular vein
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5–10 cm length, 2 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Lateral-oblique X-ray view of the cervical spine
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (70–75°C for 60 s)
• Stellate ganglion pulsed RF/continuous RF [12, 49–51]
Information: Effective in the treatment of complex regional pain syndrome and
posttraumatic stress disorder
Target: It is situated at the level of C7
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5–10 cm length, 2 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Supine, prevent patient swallowing during procedure!
View: Antero-posterior X-ray view of the cervical spine
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (70–75°C for 60 s)
Attention: Ask the patient to phonate (recurrent laryngeal nerve!), Horner’s syndrome!
• Thoracic sympathetic ganglion pulsed RF/continuous RF [12, 52–54]
Information: Effective in the treatment of complex regional pain syndrome, palmar
hyperhidrosis and compensatory hyperhidrosis of the trunk
Target: It is situated at the levels of T4, T2, T3 and T6
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 5–10 cm length, 2 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior X-ray view of the thoracic spine
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Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (75–80°C for 60–90 s)
Attention: Pneumothorax!
• Splanchnic nerve pulsed RF/continuous RF [12, 55–58]
Information: Effective in the treatment of chronic abdominal pain, chronic pancreatitis
and cancer pain
Target: It is situated at the level of T11 at the costovertebral angle (about 4 cm from the
midline)
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 15 cm length, 2–5 mm active-curved tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior X-ray view of the thoracic spine
Treatment modality: Pulsed RF (42°C for 120 s), continuous RF (75–80°C for 60–90 s)
Attention: Pneumothorax!
• Lumbar sympathetic ganglion continuous RF/pulsed RF [12, 59–61]
Information: Effective in the treatment of complex regional pain syndrome, plantar
hyperhidrosis, chronic pelvic and perineal pain and cancer pain
Target: It is situated at the level of L4, L2 and L3
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 15 cm length, 2–5 mm active-pinned tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior-oblique and lateral X-ray view of the lumbar spine (no double
end plate)
Treatment modality: Continuous RF (80°C for 90 s), pulsed RF (42°C for 120–300 s)
d. Miscellaneous procedures
• Trigeminal ganglion continuous RF/pulsed RF [12, 62–64]
Information: Effective in the trigeminal neuralgia treatment of combined pulsed and
continuous radiofrequency
Target: Foramen ovale
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 10 cm length, 2–5 mm active-pinned tip (with matching
electrode) of the RF, the grounding line




View: X-ray beam in an antero-posterior axis over the head, move the axis of the
intensifier caudo-cranially so that the X-ray beam makes an angle of 45°, next, 45–50°
between the sagittal and the vertical planes. Lateral control (Clivus must be seen!)
Treatment modality: Continuous RF (60°C for 60 s, followed by; 65°C for 60 s, followed
by; 70°C for 60 s, followed by; 75°C for 60 s, and next, 80°C for 60 s), pulsed RF (42°C
for 120–240 s)
Attention: The procedure is very painful (Sedoanalgesia may be required!), CSF may
be seen (If so, position is correct). Exhibit eye movements or facial contractions may be
seen (If so, position is incorrect), blood may be seen (If so, position is incorrect),
contractions of the masseter muscles can be seen (If so, position is incorrect), corneal
reflex should be protected!
• Intradiscal RF/pulsed RF [12, 65, 66]
Target: Posterior anulus tear
Required equipment: Mobile C-arm fluoroscopic X-ray systems, RF lesion generator,
the cannula (a 22-gauge, 15 cm length, 2–5 mm active-pinned tip (with matching
electrode) of the RF, the grounding line
Patient position: Prone
View: Postero-anterior-oblique view of the lumbar spine (no double end plate)
Treatment modality: Continuous RF (50°C for 120 s, followed by; 55°C for 120 s,
followed by; 60°C for 120 s, and next; 65°C for 240 s), pulsed RF (42°C for 120–900 s)
Attention: Monitor external temperature of disc, never exceeds 44°C
• Occipital nerve pulsed RF [12, 67, 68]
Information: Effective in the treatment of occipital neuralgia, migraine and cervicogenic
headaches
Target: Greater occipital nerve (C2), lesser occipital nerve (C3)
Required equipment: RF lesion generator, the cannula (a 22-gauge, 5 cm length, 4 mm
active-pinned tip (with matching electrode) of the RF, the grounding line, ultrasonog‐
raphy
Patient position: The sitting position
View: Occipital artery can be viewed with ultrasonography
Treatment modality: Pulsed RF (42°C for 180–600 s)
Attention: Temperature not to exceed 42°C
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• Suprascapular nerve pulsed RF [12, 69–71]
Information: Effective in the treatment of adhesive capsulitis, chronic shoulder pain
Target: Suprascapular notch
Required equipment: RF lesion generator, the cannula (a 22-gauge, 10 cm length, 5 mm
active-pinned tip (with matching electrode) of the RF, the grounding line, ultrasonog‐
raphy
Patient position: The sitting position
View: Suprascapular artery can be viewed with ultrasonography
Treatment modality: Pulsed RF (42°C for 180–600 s)
Attention: Temperature not to exceed 42°C, Be careful about pneumothorax!
• Percutaneous cervical cordotomy [12, 72–74]
Information: Indicated for unilateral pain due to malignant disease, when the pain is
not responsive to drug therapy or other less invasive methods of treatment. The patient
cannot be sedated
Target: C1/C2 intervertebral space, lateral spinothalamic tract
Required equipment: RF lesion generator, the cannula (a 22-gauge, 5–10 cm length, 2
mm active-pinned tip (with matching electrode) of the RF (Cordotomy kit!), the
grounding line, computerized tomography
Patient position: Supine
View: Lateral view of cervical spine
Treatment modality: Continuous RF (75°C for 60 s, followed by; 75°C for 60 s, followed
by; 75°C for 60 s, and next; 75°C for 60 s)
Attention: Working on the side opposite to the pain! Protect motor fibers!
Also, pulsed RF are reported in the literature that it can be used in treatment of Morton's
neuroma [13], coccygodynia [14], pudendal neuralgia [75], vaginismus [76], carpal tunnel syndrome
[77], chronic hip pain [78], post herniorrhaphy pain [79], chronic inguinal neuralgia [80], plantar heel
pain [81], osteoarthritis [82], intra-articular pain [83], plantar fascitis pain [84], tarsal tunnel
syndrome [85], myofascial pain syndrome [86], postamputation phantom pain [87], meralgia paresthe‐
tica [88], lingual neuralgia [89] and chronic testicular pain [90].
This chapter suggests the use of continuous and pulsed RF with a minimally invasive proce‐
dure for patients with chronic pain as an alternative to surgical treatment and it might be an
additional option among non-surgical treatment methods. On the other hand, further random‐
ized prospective controlled studies in patients with chronic pain are needed to fully evaluate
the effectiveness of continuous and pulsed RF.
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Abstract
Epiduroscopy is a relatively new technique used in the evaluation and treatment of low
back  pain  via  advancements  in  optical  fiber  technology.  As  a  minimally  invasive
endoscopic technique, it allows for direct endoscopic imaging of the epidural space and
helps the patients for the pain management who having post–lumbar surgery syn‐
drome (PLSS)  and other  cases  of  low back pain and radiculopathy.  An advanced
understanding of the anatomy of epidural space and adjacent structures are also essential
for positive and successful clinical outcomes. The use of epiduroscopy in the pain clinic
is performed as a day procedure, and the patient is awake and can communicate with the
doctor. During an epiduroscopy, thin tubes with a bright light and tiny fiberoptic camera
at the end are inserted through the sacral hiatus into the epidural space around the dura
and guided up toward the affected site. Anterior epiduroscopy and epiduroscopic laser
neural decompression (ELND) have been recently introduced in treating herniated disc
decompressions, and chronic low back pain and radicular pain, respectively. The most
common complications of epiduroscopic approach are the pain in the intervention point,
dural puncture, and headache.
Keywords: epiduroscopy, anterior epiduroscopy, epiduroscopic laser discectomy,
post–lumbar surgery syndrome (PLSS), low back pain, chronic pain, epidural space
1. Introduction
Epiduroscopy, also known as spinal endoscopy, which is directly visualize the epidural space
with a percutaneously minimal invasive inserted fiberoptic scope. Epiduroscopy is a relative‐
ly new diagnostic and therapeutic technique developed in the [1] performed to treat the low
back pain, specifically radicular pain in which the epidural space is directly visualized on a
video monitor. The development of epiduroscopy is connected to the integration of fiber‐
optic technology with computer‐enhanced imaging for viewing the central nervous system that
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
is miniaturized enough to be inserted into the epidural space. The fiber‐optic visualization would
be easy and safe to apply in medical practice and has made a major contribution to advances in
pain medicine. In this way, the epidural space can be identified for the cause of pain and other
neurological signs by distinguishing the anatomic structures and pathological structures.
Epiduroscopy involves looking inside the epidural space that contains nerves who are pain
generators inside of the spinal column that connect the spinal cord to the rest of the body. An
epiduroscopy involves insertion of a tiny fiber‐optic camera attached to a catheter into the
epidural space through a small incision in the sacral hiatus near the tail bone. The areas of
concern can then be visualized by guided up towards the affected nerve roots. Afterward, the
adhesions can be cut away and local anesthetic and steroid solutions can be injected.
The increased attention has been paid to epiduroscopy to deliver accurate diagnosis and
treatment for chronic pain. Recently, as a result of these efforts, epiduroscopically assisted laser
therapy has been reported for multiple lesions such as discectomy [2]. Epiduroscopy is
expected to provide successful outcomes in the diagnosis and treatment of intractable low back
and leg pain where even epidural steroid injection is not efficacious for pain relief and pain
recurs after operation.
2. History of epiduroscopy
Epiduroscopy was considered a method to study the spinal anatomy, and then improvements
allowed its employment as therapeutic approach in the diagnosis and treatment of pain.
Clinicians have been working with various types of endoscopes for over 80 years, with varying
degrees of success.
In the 1930s, Burman started the first study on epiduroscopy and reported direct visualization
of the spinal canal with arthroscopic equipment to examine the anatomy of the vertebral
column that were removed intact from human cadavers [3].
The first use of the instrument on patients did by Stern in1936 for the direct observation of the
posterior roots for rhizotomies and for the treatment of spastic conditions.
Later, Pool developed this system which did not have any recording and imaging system and
applied the technique clinically on over 400 patients. He could diagnose conditions such as
neuritis, herniated disc, neoplasms, adhesions, and venous congestion [4].
Afterward, researchers focused on visualizing the spinal canal, however, there was no further
remarkable progress on endoscopy in the literature until the late 1950s.
The key breakthrough for clinical application of this technology is the development of the first
flexible endoscope in 1958 by Hirschowitz et al. [5] that gave rise to enormous advances in
diagnostics and therapy.
In the late 1960s and early 1970s, the Japanese researcher Ooi and Morisaki [6] developed an
instrument for intradural and extradural examinations that combined a flexible light source
with rigid optics. The fiber‐optic light source technology protected the tissues from heat injury,
since the fibers absorb infrared rays and reflect visible rays.
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In 1991, Saberski and Kitahata [7] considered clinical use of these devices for the placement
into the epidural space as a diagnostic tool where the caudal approach to the epidural space
offer advantage over the paramedian lumbar approach. The authors reported that the caudal
approach facilitated correct catheter positioning for administration of epidural steroid for the
treatment of radiculopathy.
In 1993, Leu et al. [8] used endoscopies for therapeutic intervention in addition to diagnostics,
and performed peridural and intraductal endoscopies in patients.
Schutze et al. [9] conducted the first video‐optic examinations of the lumbar epidural space in
chronic patients with a flexible catheter‐secured epiduroscopic unit.
Epiduroscopy received approval through the United States Food and Drug Administration
(FDA) in 1996 for visualization of the epidural space.
Recently, minimal invasive and microsurgical techniques such as epiduroscopic laser discec‐
tomy have been introduced and used for chronic low back pain and post–lumbar surgery
syndrome (PLSS) which was called before as false back surgery syndrome (FBSS). Considering
the ongoing development trends in the area of microsystems technology, epidural endoscopy
has an increasing significance of invasive intervention in pain medicine.
3. Indications and contraindications
The pain physician's major responsibilities involve treating unexplained pain symptoms and
effective pain management. It can be difficult to classify and treat chronic spinal pain syn‐
dromes.
Therefore, the conformity between clinical examination, imaging results, diagnostic blocks,
and epiduroscopy is the backbone to ascertain the cause of pain and to establish a diagnosis
in clinical decision.
Epiduroscopy has the advantage of visually identified structures in the epidural space such
as hyperemia, changes in vascularity, fibrosis and adhesions, lateral recess stenosis, disk
herniation, and ligamentumflavum hypertrophy. Relative clinical indications for epidurosco‐
py consist in diagnostic and therapeutic of pain syndromes.
The main indication for epiduroscopy used to be for diagnosis of the sources of pain. Recently,
therapeutic is the main indication of the epiduroscopy due to the ability to the treatment of
these sites with accuracy. Diagnostically, use of the procedure provides a better view of
pathological and anatomical structures and circumstances. Obviously, success of treatment
depends on the underlying pathology. Therefore, success or failure of treatment can be used
as a measure of the validity of diagnostic parameters obtained through epiduroscopy [10, 12,
13].
As a therapeutic technique, epiduroscopy includes procedures such as direct application of




stimulation electrodes under direct vision (radio frequency therapy, spinal cord stimulation)
and discectomy. Additionally, conscious sedation in patients is administered in order to
provide response to stimulated pain‐generating areas. Further, epiduroscopy has the potential
not only to reduce the incidence of surgery but also to the treatment of post–lumbar surgery
syndrome.
Radiculopathy associated with any of the following signs or symptoms is also an indication
for epiduroscopy: failed response to epidural steroid injections, filling defects caused by
adhesions, post‐laminectomy failed back syndrome, and failed conservative back therapy.
The following indications were defined by the consensus committee of the foundation of World
Initiative on Spinal Endoscopy (WISE) in 2006 [11]:
To improve diagnosis:
• Diagnosis of clinically relevant epidural pathology, if pain can be attributed to epidural
space (spinal canal) structures based on current history, physical examination and suppor‐
tive present‐day laboratory investigations
• Biopsy for histopathological and/or histochemical analysis
• Provocative stimulatory tests (e.g., electrical, light, mechanical)
To provide treatment:
• Irrigation
• Direct application of therapeutic agent
• Direct lysis of adhesions/scar tissue with physical or chemical agents (e.g., mechanical,
pharmacological, laser, radio frequency)
As a supportive tool:
• Placing catheter systems (epidural, spinal)
• Implanting stimulation electrodes (spinal cord stimulation)
• As an adjunct in minimally invasive surgery
• Retrieval of foreign bodies
• (Potentially) for post‐operative assessment
Contraindications for epiduroscopy
There is a need for confidence in diagnostic to consider contraindications for epiduroscopy,
and in particular of the need to differentiate between low back pain of non‐spinal origin, such
as cognitive affective disorder, and low back pain of psychological origin, for example,
compensation psychosis.
The contraindications for epiduroscopy correspond to those for epidural regional anesthesia
techniques. The contraindications for regional anesthesia can be listed as skin infections in the
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area of a cut, hemorrhagic diathesis, anticoagulant therapy, exacerbation of intercurrent illness,
flu‐like conditions, high cardio‐vascular risks, etc.
The contraindications were defined by the consensus committee of the foundation of World
Initiative on Spinal Endoscopy (WISE) in 2006 as absolute and relative [11].
The absolute contraindications are stated as follows: psychiatric diseases that potentially
interfere with informed consent and/or perception of pain, retinal disease, increased risk for
or the presence of elevated intracranial pressure, manifest bowel and bladder, dysfunction and
sensory disturbances in S2‐S4 area, cerebrovascular disease, advanced systemic diseases, septic
or dystrophic skin lesions in the sacral areas (anal fistule, sacral osteomyelitis, etc.), meningeal
cysts, meningocele, meningomyelocele, severe respiratory insufficiency (COPD), known
allergy for drugs used in the procedure, instable angina, malignancy.
Relative contraindications are as follows: psychiatric diseases that potentially interfere with
informed consent and/or perception of pain, inability to lie in a prone position for more than
60 min, severe respiratory insufficiency (COPD), drug or alcohol abuse, etc. [12, 11, 13, 10]
4. Anatomy of epidural space
The main application of epiduroscopy is in relation to the management and treatment of
chronic radicular pain. The detailed anatomy of the epidural space and its surrounding bony
and ligamentous structures is of great importance for clinicians who perform epiduroscopy.
A clear understanding of the relevant anatomy and contents of the space is essential to perform
epiduroscopy safely. Epiduroscopic screening with high video‐optic quality is enabling
displaying of the corresponding morphological structures and visual understanding of this
region.
The epidural space is formed between the dural sheath and the spinal canal that extends from
the foramen magnum of the skull to the sacral hiatus in combination with the sacrococcygeal
ligament. It is bounded superiorly by the fusion of the spinal and periosteal layers of the dura
mater at the foramen magnum, and inferiorly by the sacrococcygeal membrane. The epidural
space contains the dural sac, the anterior and posterior spinal nerve roots, the extradural
venous plexus, spinal arteries, lymphatics, filum terminale and fatty tissue. The anterior and
posterior spinal nerve roots are within the dural sac. The dural sac generally ends at the level
of the S2 vertebral body and its continuation known as the filum terminale [14].
Anterior or posterior approach to the lumbar epidural space must be used in epidurocopy.
Although posterior epiduroscopy can theoretically be performed at any level of the spinal
column and through the sacral hiatus, the anterior epiduroscopy must be via caudal approach.
Anterior epiduroscopy is the most recent longitudinal approach to the entire lumbar epidural
space and provides a significant improvement in the treatment of low‐back and leg pain [15].
The sacrum is a wedge‐shaped triangular bone at the base of the spinal column that forms
from the naturally fused five sacral vertebrae. The sacrum is held in place between the two




The lamina of the lowest segment of the sacrum is incomplete; therefore, there is a gap which
is called the sacral hiatus in the anotomical structure. There are two bony projections that are
called the sacral cornua, and the sacrococcygeal ligament which covers this U‐shaped space
posteriorly. Both of these structures are represent important clinical landmarks when needles
are placed into the caudal canal. Penetration of the sacrococcygeal ligament provides direct
access to the epidural space of the sacral canal. A superiorly continuation of the sacral canal is
the lumbar spinal canal.
Since the spinal cord ends near the level of the second lumbar vertebra, this canal does not
carry the spinal cord but contains the epidural venous plexus and is filled with fat, which is
subject to an age‐related increase in density [16]. Most of these vessels are intensified in the
anterior portion of the canal. The advancement of needles or catheters cephalad into the sacral
canal can lead to trauma of both the dural sac and epidural vessels.
The epidural space contains prominent amount of epidural fat that distributes along the canal
in a predictable pattern allows injected fluid to diffuse through the epidural space and have
impact on nerve roots by the absorption of drugs. The fat in the epidural space is soft which
surrounds dura mater and protects the neural structures, and facilitates the movement of the
dural sac [21].
The spinal dura mater is a strong connective tissue membrane surrounding the cerebral spinal
fluid, the spinal cord, the anterior and posterior nerve roots, and spinal ganglia. It extends
from the foramen magnum to the sacrum. The dura is being separated by the epidural space
so is not attached to the vertebrae. Microscopic view of the dura mater consists of white fibrous
and elastic tissues arranged in longitudinal bands or flattened lamellae. Characteristics of dura
mater seen on epiduroscopic images are convex, tubular, and grey‐white with blood vessels
on the surface, giving the appearance of a road map. In epiduroscopy, a fiber‐optic endoscope
inserted into the sacral hiatus advanced upward into the epidural space. When the epiduro‐
scope advanced in the sacral canal the exact position of dural sac must be ensured via image
guidance to prevent dural sac injury because the dural sac terminates at S2 level.
The epidural space contains arteries and veins supplying the spinal cord. The epidural arteries
are relatively small and pass through the intervertebral foramina to supply adjacent vertebrae
and ligaments. The arteries are located in the lateral epidural space hence not threatened by
an advancing needle or epiduroscope. Inside, the spinal canal there is a network of large and
valveless veins running along the entire length of the vertebral column. The epidural veins
predominantly lie in the anterior epidural space and interconnected one to another to form a
venous plexus and ultimately drain into the azygous system of veins. The vertebral plexuses
with the veins of bones of the vertebral column form Batson's plexus. The intervertebral veins
are responsible for the communication between the vertebral venous plexuses which run
through the intervertebral foramina. In the lumbosacral part of the vertebral column, the
ventral venous plexus is generally larger than the dorsal plexus. The vertebral venous plexus
is subject to distension in case of increased intrathoracic or intra‐abdominal pressure because
of ascites, pregnancy, large tumors. Thus the venous plexus is thought to be involved in a
trauma during epiduroscope placement in the epidural space and increases the risk. [17, 18, 19].
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The arteries appear on epiduroscopic images as a thin red thread with pale opaque insulation
while veins cannot detectable, and pulsatile flow can be seen [20].
The epidural space communicates with the paravertebral spaces via the intervertebral
foramina where major site of action for an epidural located to nerve roots. The nerve supply
of the epidural space is via branch from the sinu‐vertebral nerves that originate from the rami
communicantes. The nerve roots lie in the posterolateral part of the epidural space where they
enter and exit the vertebral column at each level in a specific pattern. Nerve roots seen on
epiduroscopic images as grey‐white tube shape with a vessel running longitudinally down
the centre [20, 18].
The lymphatics of the epidural space are present in the region of the dural nerve roots whereas
they are absent in the nerve root itself and remove foreign materials from the subarachnoid
and epidural spaces [21].
5. Pathological findings of epiduroscopy
Epiduroscopy is the most recent, complete, and effective technique to approach the spine
through minimal invasive access means for treating persistent low‐back pain.
Spinal pain and radicular pain syndromes are both characterized by pathological and ana‐
tomical changes in the epidural space and diagnosed via epiduroscopy such as arachnoiditis,
fibrosis, stenosis, nerve root compression.
The epidural space lies between the dura mater and the walls of the vertebral canal, containing
fat and small blood vessels. The space is located just outside the dural sac which surrounds
the spinal nerve roots and is filled with cerebrospinal fluid.
Epiduroscopic view under traditional white‐light endoscopy can give us a better understand‐
ing of the pathology. Dura mater appears as either a blue‐gray or gray‐white exterior with
small blood vessels on its surface, epidural fat appears usually yellowish in color, globular,
and glistening with small blood vessel on or in it, nerve roots are white tinged with yellow
tube shape with a vessel running longitudinally down the center, ligamentum flavum seen as
a white and concave tube without vessels.
5.1. Fibrosis
The formation of scar tissue near the nerve root spontaneously or after spine surgery thought
to be the potential cause of the pain or radicular symptoms. If it binds the lumbar nerve root
with fibrous adhesions that also called epidural fibrosis. Epidural fibrosis also may restrict the
flow of medication to the nerve roots and limiting the effectiveness of epidural injections since
mechanical deformation of spinal nerve roots and dorsal root ganglions. If the patient suffers
from continued or recurrent pain directly after spine surgery epiduroscopic diagnostic
imaging technique can often pinpoint the responsible pathology of pain. It was shown that




than less extensive one, and the correlation is statistically significant [22]. None the less a
correlation between the degree of epidural fibrosis and the intensity of post‐surgical pain was
also reported [23, 24]. Epidural fibrosis is diagnosed not only in patients who have had low
back surgery but also who have anatomical abnormalities such as stenosis, instabilities and
herniated discs without surgery. There are many patients who having pathology with no pain
therefore establishing a cause and effect relationship between pathology and pain is low [25].
In the endoscopic image, epidural fibroses appear clear white and are generally avascular.
5.2. Adhesions
Epidural adhesions most commonly occurs as a complication of spinal surgery that are related
to inflammatory reactions and result in the entrapment of nerves within dense scar tissue.
Beside this can also develop following disc herniation or infection without prior surgery taking
place. Morphological changes in the supporting structures of the spine have been identified
primarily in the form of epidural adhesions. They limit the pain‐free movement and function
of structures in the intervertebral foramen and the bony vertebral canal, and prevent direct
application of medications to the affected disc and nerve root. Epidural adhesions may or may
not involve in the generation of pain therefore should be considered carefully [26, 53].
Adhesions or adhesive areas are easily visible fibrous bands of tissue with epiduroscopy that
appear clear to white and often bizarre. Epiduroscopy is used to break down adhesions by
infusion of a small amount of saline through the catheter with careful and gentle movement
of the catheter.
5.3. Chronic inflammatory processes
The visual function of epiduroscopy can be used to identify chronic inflammatory processes
in the epidural space such as epiduritis and radiculitis. Chronic inflammatory condition
increases levels of inflammatory mediators at the affected site and results increased pain.
5.4. Radiculitis
Radiculitis is pain that originates from direct pressure on the nerve roots because of inflam‐
mation or other irritation of a nerve root at its connection to the spinal column. Disc herniation,
osteophytes, thickening of surrounding ligaments, spinal stenosis, damaged intervertebral
discs, degeneration of the spine, spondylolisthesis, or scoliosis could be one of the many causes
of radiculitis.
Radiculitis symptoms start with radiating pain along the nerve path and usually accompanied
with sensations of numbness, tingling, pins, and needles. The other incorporating symptoms
of muscle weakness and loss of reflexes also present as the condition progresses. A variety of
symptoms of radiculitis can be felt anywhere in the body depending on the location of the
affected disc, and nerve root because each area of the body is controlled by nerves exit the
spinal column in pairs. For example, cervical nerve root can cause pain and other symptoms
through the arms, hands, and fingers, lumbar nerve root can radiate through the leg and into
the foot and prompting leg pain and foot pain.
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5.5. Epiduritis
Epiduritis is an acute or chronic inflammatory process of epidural structures in the epidural
space and on the outer surface of the dura mater of the spinal cord. Epiduroscopically it is
characterized with cardinal symptoms such as swelling, redness, and a positive pain provo‐
cation test.
5.6. Arachnoiditis
The arachnoid mater is the middle one of the three protective membranes of the central nervous
system that surrounds the brain and spinal cord. Inflammation of the arachnoid is called
arachnoiditis that subdural processes take place on the caudal fibers and the nerve root sheaths,
and characterized by severe burning pain, stinging, numbness, and neurological problems. In
the case of arachnoiditis and perineural nerve sheath fibrosis, the spinal dura mater appears
thickened and the tissue appeared to have increased vascularization. Arachnoiditis is a
complex neuropathic pain disorder with a complex etiology that affects the nerves connecting
to the lower back and legs. Adhesive arachnoiditis is most commonly present with associated
epidural fibrosis whereas epidural fibrosis can occur alone. Arachnoiditis is most frequently
seen in patients who have undergone multiple surgical procedures.
5.7. Xanthosis
Xanthosis is a yellowish degeneration with yellowish pigmentation which could be observed
in the spinal epidural space in the literature by Heavner et al. [27]. This epiduroscopy finding
in the peridural tissue adjacent to blood vessels at the left L5‐S1 intervertebral foramen
associated with radiculopathy. They administered treatment with the same equipment and
gained satisfactory reduction in the radicular pain with the treatment outcome. Thus, called
as a novo epiduroscopy finding.
5.8. Ligamentum flavum hypertrophy
Hypertrophy of the ligamentum flavum is a pathologic condition due to fibrosis and scar tissue
formation that contribute to cord compression radiculopathy. Hypertrophy of the ligamentum
flavum can be rarely encountered in the lumbar region however more common in cervical and
thoracic regions. Hypertrophy of the ligamentum flavum is usually involved in the patho‐
genesis of spinal stenosis which can cause loss of disc height, reduce the diameter of the spinal
canal and compress the dural sac and nerve roots. A multilevel detailed examination of the
epidural space is now possible with epiduroscopy and directly observation of hypertrophied
ligamentum flavum can be satisfactorily achieved [28, 29].
5.9. Cysts in the spinal canal
The patients may suffer from recurrent pain and/or troublesome new symptoms such as failed
back surgery syndrome after surgical treatment. Some cyst types may also be present in the
different levels of the spinal canal such as synovial cyst of a lumbar facet joint, often cause




imaging, due to the packed up anatomy and the inflamed cyst being not easily identified from
adjacent structures confirmation of the diagnosis with fluoroscopy, MRI or CT may be
necessary to assess the contents of spinal canal [30]. Minimally invasive technique such as cyst
rupture by epiduroscopy has the potential for fenestration of cyst either post‐operative or not.
Jin et al. successfully removed a lumbar facet joint cyst at L4/5 level by epiduroscopy. Epi‐
duroscopy usage as a support to diagnose and therapy of the cyst that results compression on
the radicular nerve would be favorably an alternative technique over conventional surgery in
the future [31].
6. Technique of epiduroscopy
Before the epiduroscopy process, the patient's history should be reviewed as expeditiously as
possible and a comprehensive physical exam should be carried out. Detailed preoperative
knowledge of the patient's neurological assessment is necessary to recognize the post‐
operative neurological complications. The specialized nerve tests such as EMG, NCV and SSEP
to investigate the functioning of the nervous system, and imaging studies like CT scans or MRI
scans should be completed in the preoperative setting. The skeletal structures of the sacrum,
the level of termination and position of the bottom of the dural sac particularly on T2‐weighted
MRI, the evaluation of the anterior and posterior epidural spaces should be performed
previously.
Epidural bleeding during epiduroscopy constitute extremely rare, however, taking conven‐
tional precautions to prevent is substantial. NSAIDs use should be stopped 24 h before and
aspirin should be stopped 3–4 days before procedure in the perioperative period. It is also
generally recommended to stop any oral anticoagulant before open surgery. In addition to
complete blood count (CBC) that also called hemogram, an evaluation of basic coagulation
Figure 1. Optimum design of the operating room at which the epiduroscopy takes place.
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parameters should be ordered for prothrombin time (PT) with a partial thromboplastin time
(PTT), and the international normalized ratio (INR) calculation based on results of PT to
monitor individuals in the perioperative period. The operating room is equipped with a
fluoroscopy table, C‐armed scopy device, holmium laser, light source, and imaging device
(Figures 1–3).
Figure 2. Anesthesia device in front of the operating table.
Figure 3. C‐armed scope and video monitoring system to the right of operating table, Holmium laser device and tradle
close to applicator.
Perioperative antibiotic prophylaxis therapy in general administration of ceftriaxone 1 g




operation room and placed in the prone position on the fluoroscopy table with a pillow under
the abdomen to correct the lumbar lordosis.
Figure 4. After setting aseptic conditions, sterile dressing gets covered over procedure area.
The practice of aseptic technique is maintained and patient and fluoroscopy are covered the
sterile dressing (Figure 4). Intravenous 2 mg midazolam and 50 mcg fentanyl is administered
for performing the procedure under conscious sedation.
Figure 5. Insertion of 22G spinal needle passing through sacral hiatus.
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Figure 6. Fluoroscopy image of 22G spinal needle after passing through sacral hiatus.
Under C‐arm (fluoroscope) lateral image guidance, intradermal, and subdermal infiltration of
local anesthetic is injected by a 22G spinal needle, then 8–10 mL 1% lidocaine injection is
administered to epidural space by passing through the sacral hiatus (Figures 5 and 6). This
will greatly reduce the abnormal pain and pressure feeling of patient during advancing the
trocar through the narrow caudal canal, will prevent in vivo motion in patient and there will
be no need to increase the sedation of prone‐positioned patient so that facilitates ease of
application for clinician.




Figure 8. Image of trocar after its stilette is removed.
Figure 9. The lateral fluoroscopic image of trocar in the caudal epidural space after passing through sacral hiatus.
Lateral intradermal and subdermal incision of 0.5 cm is made in the skin with No. 11 sharp
disposable scalpel where 22G spinal needle introduced. If you notice some bleeding from the
incision simply apply firm pressure to the area with surgical gauze. The trocar is, outer
diameter 4.2 mm and inner diameter 3.5 mm, and then advanced through sacral hiatus at the
skin incision point with C‐armed scopy guidance (Figures 7–9). There is a slight loss of
resistance as the trocar enters the caudal canal. Repeat antero‐posterior (AP) images will be
taken during the trocar advancement and will assure that the trocar direction does not stray
from midline. AP image confirmation of proper placement of the trocar in the mid‐line of sacral
foramina will verify its position within the same line of pubic symphysis. The C‐armed scopy
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is rotated in a lateral direction once trocar is held on the posterior to dural sac, where termi‐
nation and position of the bottom of the dural sac was determined previously on MRI, and the
central stylet of the trocar is pulled out.
Figure 10. Image of epiduroscope catheter tip.
Spinaut‐V® epiduroscopy catheter is 33 cm in length and outer diameter 3.2 mm in width. The
catheter has two working channel in 1.2 mm diameter where one is maintained on the top and
the other is at the bottom of device. (Figure 10). The top canal is for using a high resolution
fiber optic camera, and the bottom canal is for using a laser probe or biopsy forceps that can
ablate a herniated disc or epidural scar tissue (Figures 11 and 12). The device has an ergonomic
design for handling the epiduroscope. There is a controller gear on both sides of catheter to
steer the catheter in 2‐way directions (right or left). There is a dual port on the back of controller
gear look like a dual exhaust. (Figure 13). On the left input, the canal allows insertion of camera
and physiological saline solution administration at the same time to give a clear view of the
inside of the epidural space during the procedure (Figure 14). Extension tubing for extension
line is connected to the left input and attached to physiological saline bag 150 mL via a 3‐way
stop‐cock. A 20‐mL injector is also connected to the 3‐way stop‐cock. Physiological saline
solution is injected either by exerting a light pressure on the injector or slow infusion. In the
right input; there is a tube outlet that allows suction of blood or other given solutions. Non‐
ionic radio‐opaque material is preferred to be administered through the right canal because it
is highly dense and can stick to camera that results blurred image. This happens more
frequently when it is administered through left canal. Additionally; injecting physiological
saline along with radio‐opaque material will pull away the material away from the camera.
The best way of avoiding the blurred image and obtaining good visualization of the epidural





Figure 11. Camera and laser probe from superior and lateral taken from epiduroscope catheter tip.
Figure 12. Laser probe and camera are superposed in the upper shooting.
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Figure 13. Fiberoptic camera advances from the left input (1), laser probe advances from the right input (2).
Figure 14. Physiologic saline line (1).
In the case of access to posterior epidural space, epiduroscopy is passed through the trocar
and advanced to S1 vertebra level with guidance of C‐armed scopy. After the epiduroscopy is
placed, 10 mL of radio‐opaque material is injected for epidurography. The monitoring of
epidural space is started after re‐evaluating the clinical condition of patient, MRI, and
epidurography results.
The epiduroscope is rotated 90° laterally to gain access into the anterior epidural space and
advanced through trocar under the guidance of C‐armed scopy lateral imaging. While
attempting to introduce epiduroscopy into the anterior epidural space rotating the scope too




that cause sensation of pain may lead patient movement and induce loss of the position of the
patient. Following the access into the anterior epidural space, epiduroscope is returned to
original neutral position.
Figure 15. The lateral fluroscopic image of epiduroscope tip at S1 level.
Figure 16. The AP fluroscopic image of epiduroscope tip at S1 level.
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Once epiduroscope inserted into the anterior epidural space, the tip of the epiduroscope is
introduced to the level of S1 (Figures 15 and 16). Initial epidurography is done at the same
time to detect disc herniation or obstruction level, and compared to MRI and clinical findings.
The bulging at targeted disc level is easily seen due to obstruction to the flow of the injected
radio‐opaque material towards to cephal. By use of the AP fluoroscopy position, the end‐plates
of targeted levels are straightened. The fiberoptic camera with light is connected to
epiduroscope under sterile conditions and advanced through the left input until the
epiduroscopic end point. The camera that the light source system controlled and white
balanced prior to procedure to assure accurate tissue color is turned on. Injection of
physiological saline through the catheter placed into the epidural space would keep distend
the epidural space and keep clear the camera for a good view. The piston of physiological
saline containing injector is slightly pushed (0.15–0.20 mL/s). The amount of given hidration
must be tightly monitorized. The fiberoptic camera shouldnot get pass the end point of
epiduroscope because the vision from the camera is designed to fit the opening of epiduroscope
to point upwards. This way we obtain a crescent shaped edge beneath the monitorized view
and use this as a kind of compass. Keeping the crescent edge at the bottom part of the image
allows us proper orientation in the anterior epidural canal. While in the anterior epidural canal,
as we get the crescent at the bottom the dura will be appear at the upper side of the image on
the screen. As we are able to monitor both dura and lumbar disk at the same time, laser probe
that is introduced into respective input canal does not harm the dura and placed in the targeted
disk.





Figure 18. The final AP epidurography.
Before the termination of procedure, a final epidurography is performed to assess the efficiency
of epiduroscopy (Figures 17 and 18). If the patient did not diagnosed with diabetes mellitus
and the dura was not perforated, 80 mg of methyl prednisolone and 10–15 mg of bupivacaine
in 5 mL total volume would be injected and the trocar along with the epiduroscopy catheter
is removed.
When the procedure is over, a single suture for skin closure is applied and wound dressing is
completed. The patient is admitted to post‐op care unit and evaluated. If no abnormality is
observed the patient is discharged to the ward. The patient is immobilized for 3–4 h. Especially
in patients with disc herniation is advised to use steel corset while mobilizing. The pain in the
intervention point and headache are the most common complications of an epidural proce‐
dure. To manage this, intravenous hydration treatment and intravenous 1 gr of paracetamol
are sufficient. If there is no problem in their general clinic condition, patients can be discharged
at same day or can be admitted to the ward for one night then discharged the day after the
procedure with antibiotics and NSAIDs prescription. Because of the administration of steroids
to epidural region, 7–10 days of salt‐free diet is reasonable. Perineal care is advised cleaning
of the perineum from dorsal to front without contacting the intervention point after defecation/
urination is advised. Patients are permitted to take their first shower 1–2 days after the
epiduroscopy
7. Therapeutic anterior epiduroscopy
Epiduroscopy has been introduced as a new technique for treatment of chronic low back pain
(LBP) syndromes or herniated disks. The clinical effectiveness and cost‐effectiveness of
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epiduroscopy have been described in multiple prospective and retrospective studies although
the underlying mechanisms have not been fully investigated.
The procedures used for determination of the pathology in chronic low back pain often have
difficulty in making an accurate diagnosis. However, epidural endoscope allows visualization
of the epidural space to potentially identify the reason of LBP, therefore, to address these
problems attention has been drawn to epiduroscopy as a tool for an accurate diagnosis. In
addition to more accurate diagnosis, usage as a therapy of any adhesion or inflammation,
compression on the radicular nerve therein, and inject medications into the lesions.
7.1. Epiduroscopic laser discectomy
Disc decompression is typically performed both surgically and non‐surgically to reduce
pressure on the nerve root by removing disc nucleus while preserving disc strength with a
high success rate, [1, 2] and low complication rate [32, 33].
Technological innovations in the treatment of disc decompressions has improved the ability
to treat pathology effectively through anterior epiduroscopy that requires only local anesthetic
and conscious sedation (leading to reduced risk of accidental nerve damage), overcomes the
possible complications of surgery and general anesthesia.
Recently, epiduroscopic laser neural decompression (ELND) as another minimal invasive
technique have been introduced for chronic low back pain and radicular pain that cannot be
solved by other non‐invasive conservative treatments, including the epidural steroid injection
[34]. In spite of surgery is often considered as the next step in treating continuous chronic low
back pain, it has potential risks of post–lumbar surgery syndrome that is difficult to manage.
The incidence of post–lumbar surgery syndrome after back surgery ranges from 5 to 50% [35].
Laser is a source of monochromatic, coherent and unidirectional light that used in many fields
of medicine with diagnostic and therapeutic purposes. Disc and neural decompression,
rechanneling stenoses caused by adhesions are examples of the use of laser and expands the
range of possibilities for epiduroscopy. Researches involving lasers have been conducted on
the usefulness of epiduroscope for the patients with the post–lumbar surgery syndrome.
Epiduroscopic laser application allows treatment of low back pain and radicular pain caused
by herniated lumbar disc, adhesions or fibrosis in the epidural space depending on the
particular pathological and anatomical circumstances [36, 37].
In the treatment of patients with chronic refractory low back pain a two working channel
system of video guided catheter and subsequent application of an optical laser fiber is
established. As with the existing epiduroscopic adhesiolysis, epiduroscopic laser neural
decompression (ELND) also provides non‐invasiveness, short operating time, elimination of
the risks of general anesthesia, communication with the patient during the procedure, and
short recovery time. ELND offers a variety of additional benefits that direct treatment of the
origin of pathology by reducing the volume of the herniated disc in the affected area, direct





However, an excellent visual control is compulsory for the use of laser where the endoscope
with the flexible tip makes possible advancement fine navigation of the relatively rigid laser
fiber. Further visual control has to assured and saline infusion has to be started prior to the
laser activation.
Because of the risks of heat damage to the nerve roots induced by laser disc decompression,
treatment of adhesions near the nerve root should be avoided. Epiduroscopic laser neural
decompression can easily remove painful adhesions in the area of the nerve root that cannot
mobilized by mechanical movement of the tip of the epiduroscope.
If motor nerve paralysis occurs due to thermal damage of nerve roots during the laser treatment
as a complication, the procedure must be aborted immediately. Other complications those need
particular caution have been reported as local sensory impairment, fiber breakage, and discitis
during the laser procedure [38].
8. Complications
In spite of epiduroscopy is a safe technique as a minimal invasive procedure to reduce post‐
operative complications, the rates of complications will increase commensurate with its
increasing usage.
Complications arising during epidurocsopy therapy are mainly reported as headache,
cervicodynia, convulsions, dura tear, neurologic damage, visual impairment, infection,
general back complaints, vomiting, meningitis, radicular radiating pain, bladder, dizziness,
hypoacousia, and rectal disorders.
According to the literature, complications related to epiduroscopy are generally caused by
puncture trauma, accidental dural injury, puncture of an epidural blood vessel or epidural
bleeding, changes in the epidural pressure caused by saline infusion [39, 40, 42, 45, 49, 50]. The
knowledge on the complications and accidental symptoms, using proper epiduroscopic
equipment and ensuring optimal vision accompanied with sufficient experience in using the
epiduroscopic technique can help prevention from complications.
Post–dural puncture headache are reported relatively frequently during epiduroscopy when
attempting to carry out placement of the epiduroscopic catheter or from accidental perforation
of the dura as a result of perforation of the spinal dura mater and attributed to a rapid loss of
cerebrospinal fluid.
The dural perforation is not a serious complication unless the accidental dural perforation is
not recognized and is not responded to, otherwise, spontaneous closure of the perforated site
has also observed. Epidural blood patches are reliable in order to treat the patients’ headache
due to dural perforation during epiduroscopy within a short time [41, 43, 44, 47, 48].
It is reported by Gill and Heavner [51] that a sudden increase in epidural pressure due to the
epidural infusion causes compression of the optic nerve and compression of the vessels that
results to a rupture and in turn to retinal haemorrhage.
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Another clinically relevant complication described by Mizuno et al. [46] in which encephal‐
opathy and rhabdomyolysis was induced by the administration of the contrast agent iotrolan
during epiduroscopy.
Our experience has also shown that the amount of liquids delivered to the spinal canal should
be calculated precisely during implementation of the epiduroscopy procedure, and infusion
rate of drug or radiopaque substances should be at a low speed to avoid from complications.
When saline fluid was infused too quickly this leaded to hypertension, decreased oxygen
saturation, respiratory arrest, and loss of consciousness where epiduroscopy was immediately
terminated [52].
The incidence of complications is inversely proportional to professional skills of practitioner
and the number of years of experience. It should be bear in mind, there are risks associated
with medical procedures in the spinal region, even when it is performed properly and
conscientiously.
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